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ABSTRACT 
 
MOLECULAR MECHANISMS OF ALTERNATIVE SPLICING REGULATION:  
AN INVESTIGATION OF THE SPLICEOSOME REPRESSED BY HNRNP L ON CD45 EXON 4 
Ni-Ting Chiou 
Kristen W. Lynch 
           Alternative splicing is a key step in gene regulation and involves the differential 
selection of splice sites to generate different pre-mRNA transcripts. It has been shown 
that 90-95% of pre-mRNAs are alternatively spliced in human cells. Pre-mRNA splicing 
is catalyzed the spliceosome, which consists mainly of the U1, U2, U4, U5 and U6 
snRNP, and about a hundred of non-snRNP proteins. Splicing regulators that bind to 
enhancer or silencer elements on the pre-mRNA can alter assembly of these spliceosome 
components. Understanding how splicing regulators control spliceosome assembly will 
bring insights to the prediction of splice site choices. In our lab, we used CD45 as a 
model gene for studying alternative splicing and spliceosome assembly. The exonic 
silencer sequence (ESS1) within CD45 exon 4 is bound by hnRNP L to induce its 
skipping. HnRNP L represses spliceosome assembly at a step after the binding of U1 and 
U2 snRNP on either side of the exon. My goal is to understand how hnRNP L perturbs 
U1 snRNP binding at the 5’ splice site (5’ ss) to cause the skipping of CD45 exon 4.  
          Using psoralen- and UV-crosslinking analysis, U1 snRNP and other protein 
components that associate with the sequences around the 5’ ss within the hnRNP L-
repressed spliceosome complexes were compared with the control complexes. These 
studies revealed that hnRNP L recruits hnRNP A1 to the 3’ end of exon 4 to induce an 
extended pairing interaction between the U1 snRNA and the 5’ ss. Splicing assays in 
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vitro and in cells further demonstrated that hnRNP A1 and the U1 snRNA binding at the 
3’end of exon 4 are required for hnRNP L-mediated skipping of exon 4. Further analysis 
of other exons repressed by hnRNP L or A1 suggests the potential for the extended U1 
pairing interactions with these exons. These data imply that induction of U1 interactions 
with the exonic region nearby a 5’ ss could be a widespread mechanism in inducing the 
skipping of exon. To further determine how the extended U1 binding affects the 
subsequent spliceosome assembly steps, hnRNP L-repressed spliceosome complexes 
were purified. This analysis revealed that association of U6 snRNP with the 5’ss, and 
recruitment of NTC components, are blocked in the hnRNP L-repressed complexes. 
Moreover, enhancing binding of U6 to the 5’ss overcomes the effect of the extended U1 
interaction, thereby increasing the splicing of the hnRNP L-repressed substrate. These 
results provide the first example showing that the U1/U6 switch, a structural 
rearrangement during the catalytic activation of the spliceosome, is a naturally occurring 
point for regulating alternative splicing. This study also suggests that splicing regulators 
that alter U1 binding, or spliceosome components that associate with the 5’ ss after U1 
binding, are important factors for determining the usage of the 5’ss. 
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Chapter 1 
Introduction  
 
                 In 1980, the first example of the pre-mRNA alternative splicing, the immunoglobin 
µ heavy chain gene, was discovered. In 2008, with the advances of the RNA sequencing 
techniques, it was shown that 90-95% of pre-mRNAs are alternatively spliced in the 
human cells (Pan et al., 2008; Wang et al., 2008). Now, alternative splicing is widely 
recognized as a critical step in regulating gene expression. As alternative splicing is 
tightly regulated by a multitude of RNA-binding proteins or RNA-protein complexes, 
mutations either in the splice sites, or in the splicing regulatory sequences that interfere 
the assembly of splicing complexes, are responsible for at least 10% of human genetic 
diseases (Cooper et al., 2009; Wang and Cooper, 2007). Thus, one of the important 
questions in the current field of RNA biology is how splicing complexes are regulated by 
splicing regulators to achieve alternative splicing. In this chapter, I provide an overview 
of alternative splicing, splicing complexes, and the model systems for studying the 
regulation of alternative splicing. 
 
1.1 Regulation of alternative splicing by cis-regulatory elements 
          After being transcribed from a gene locus, the pre-mRNA undergoes extensive 
processing steps to become the mature mRNA. The properly processed mRNAs are then 
transported into the cytoplasm for translation. Among post-transcriptional processing 
steps, the three main steps are 5’ capping, 3’ polyadenylation and RNA splicing. The 
splicing step involves the removal of introns and ligation of the flanking exons to 
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generate the coding region of mRNA. In the alternative splicing processes, portions of the 
transcripts are differentially excluded or included to generate different mRNAs from a 
single gene (Black, 2003). When the variable region contains an exon, alternative 
splicing generates mRNAs that encode different protein isoforms (Figure 1.1; cassette 
exon). Additionally, when alternative splicing occurs within the untranslated regions 
(UTRs), it generates mRNAs containing different 3’ or 5’ UTRs, which allows the 
regulation of mRNA translation by 5’- or 3’-UTR-binding factors (Figure 1.1; alt 3’ end 
and 5’ end). Therefore, alternative splicing provides the opportunities for regulation or 
enrichment of both proteome and transcriptome.  
      
     
Figure 1.1 The common alternative splicing patterns. In the cassette exon pattern, the 
variable exon (pink box) is flanked by the constitutive exons (gray box). The alternative 
3’ end or 5’ end splicing regulation results in generating the mRNAs that differentially 
exclude or include the variable 3’ UTR (blue box) or 5’ UTR (green box) while keeping 
the same constitutive UTR (gray box). Here, introns are depicted thick black lines. Blue 
and black lines indicate the splice sites used in the exclusion and inclusion of the variable 
regions, respectively.  
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        In general, alternative splicing is regulated by the cis-regulatory elements in the pre-
mRNA (Matlin et al., 2005). The exonic or intronic splicing enhancer (ESE or ISE) 
enhances the inclusion of the variable exon. In contrast, exonic or intronic splicing 
silencers (ESI or ISI) induce the skipping of the variable exon (Figure 1.2). These cis-
regulatory elements are typically associated with splicing regulators to regulate the 
assembly of the spliceosome on the pre-mRNA to direct the pre-mRNA splicing choice. 
Most of these splicing regulators are subject to transcriptional or post-transcriptional 
regulation in response to different signal-transduction pathways (Martinez et al., 2012). 
In response to T-cell receptor signaling, GSK3 has been shown to phosphorylate the 
splicing regulator PSF to induce the skipping of CD45 exons (Heyd and Lynch, 2010). 
Additionally, in cancer cells, elevated production or phosphorylation status change has 
been observed in several splicing regulators, which contributes to alternative splicing of 
proto-oncogenes (David and Manley, 2010). 
 
     
Figure 1.2 Cis-regulatory elements within the exonic and intronic regions that 
regulate alternative splicing. ISS and ESS (red boxes) repress the inclusion of the 
variable exon. In contrast, ESE and ISE (green boxes) enhance the inclusion of the 
variable exon. Other schematic depiction is the same as in Figure 1.1. Adapted in part 
from (Matlin et al., 2005). 
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1.2 Pre-mRNA splicing is catalyzed by the spliceosome 
         The pre-mRNA splicing reactions involve three reactive regions in the pre-mRNA, 
including the 5’ splice site (5’ ss), 3’ splice site (3’ ss) and branch point site (BPS) 
(Figure 1.3A). These reactive regions are all defined by short consensus sequences. In 
addition to these three regions, metazoan introns contain a conserved polypyrimidine 
tract (PPT) between the BPS and 3’ ss.  
          The catalytic spliceosome is mainly consisted of U2, U5, and U6 small nuclear 
ribonucleoprotein (snRNP). Each U snRNP contain its unique snRNA and 10-20 proteins 
(van der Feltz et al., 2012). The catalytic spliceosome interacts and brings the splice sites 
together to allow the two transesterification catalytic steps to occur (Figure 1.3B). In the 
first catalytic step, the 5’ss is cleaved with concurrent formation of a covalent bond 
between the first nucleotide of the intron and an A residue at the BPS. In the following 
step, the catalytic spliceosome excises the lariat intron and joins the 5’ and 3’ exons to 
generate mature mRNA (Figure 1.3B, lariat intron and mRNA). 
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Figure 1.3 Catalysis of pre-mRNA splicing in the spliceosome. (A) The consensus 
sequences that define exon/intron boundaries. Consensus nucleotides are indicated above 
the line (Y=U or C; R=G or A), and the term for sequence is shown below. SS, splice 
site; PPT, polypyrimidine tract; BPS, branch point site. (B) Schematic of the two 
transesterification steps that occur in the catalytic spliceosome. For simplicity, only U2, 
U5, U6 snRNP and nineteen complex (NTC) are shown in the catalytic spliceosome. The 
first arrow shows the direction of the nucleolytic attack at the G nucleotide at 5’ss by the 
A nucleotide at BPS. The second arrow depicts that the end of the upstream exon attacks 
the G nucleotide at the 3’ss. 
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1.3 Spliceosome assembly pathways 
1.3.1 Canonical intron-defined spliceosome assembly pathway 
        The spliceosome, the largest RNP machine in the nucleus, recognizes and positions 
the reactive regions in the pre-mRNA to catalyze splicing. To assemble the catalytic form 
of the spliceosome on the pre-mRNA, it involves five snRNPs: U1, U2, U4, U5 and U6 
snRNP and additional non-snRNP associated proteins to assemble on the pre-mRNA 
substrate in a stepwise way. The stepwise assembly of snRNPs on the pre-mRNA forms 
the pre-spliceosomal E, A, B and finally, catalytic-spliceosomal C complex (Figure 1.4) 
(Wahl et al., 2009).  
         To begin the assembly of the spliceosome, U1 snRNP engages with the 5’ splice 
site, while SF1 binds to the BPS, in an ATP-independent manner to form the pre-
spliceosomal E complex (Figure 1.4; E). In metazoan systems, the 65 and 35 subunits of 
the U2AF protein heterodimer also bind to the PPT and 3’ss respectively during this 
ATP-independent step to further promote correct identification of the 3’ end of the intron. 
In the presence of ATP, several rearrangements of the snRNPs then occur, to progress 
assembly from the E to A, B and C complex. The first rearrangement is that U2 snRNP 
displaces SF1 from the BPS to form the A complex (Figure 1.4; A). At this point, the pre-
assembled U4/U6.U5 tri-snRNP and nineteen complex (NTC) are recruited to form the B 
complex (Figure 1.4; B). The releasing of U1 and U4 snRNP from the B complex results 
in the formation of the Bact complex  (Figure 1.4; Bact) (Bessonov et al., 2010). 
Subsequent to the Bact complex formation, Prp2, a RNA helicase, triggers the formation 
of the covalent bond between the 5’ end of the intron and the A residue, which generates 
the C complex (Warkocki et al., 2009) (Figure 1.4; C). In the C complex, the subsequent 
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second catalytic step occurs to remove the lariat-intron and ligate the flanking exons 
(Figure 1.3B).  
           During the stepwise assembly processes, multiple combinatorial interactions are 
generated between the spliceosomal components and the reactive regions of the substrate. 
Although these reactive regions have very limited conservation (see Figure 1.3A), the 
multiple interactions provide the spliceosome an opportunity to “check and recheck” the 
fidelity of interactions, thereby increasing the accuracy of site selection (Staley and 
Guthrie, 1998). Moreover, the transitions among these spliceosomal interactions also 
provide a multitude of potential points for regulating alternative splicing. 
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Figure 1.4. Spliceosome assembly pathway. The E complex mainly involves binding of 
the U1 snRNP, SF1 and U2AF at the 5’ and 3’ ss, respectively. U2 snRNP is then 
recruited to the 3’ss to form the A complex. The U1 and U2 snRNP in the A complex 
recruit the tri-snRNP to form the B complex. The releasing U1 and U4 snRNP from the B 
complex generates the Bact complex. Prp2 triggers the first catalytic step to occur in the 
Bact complex to generate the C complex. 
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1.3.2 Exon-defined spliceosome assembly pathway 
        The combinatorial interactions described above are built across the introns. However, 
the average lengths for exons and introns of human protein-coding genes are, respectively, 
145 and 3364 nucleotides (Consortium, 2004). Since the exons are significantly shorter 
than introns, it is expected that initially identifying exons during the spliceosome 
assembly would help the splicing components to be deposited across the introns more 
precisely, and hence avoid the use of the cryptic splice sites. Thus, it is envisioned that 
the cross-exon interactions of the snRNPs occur first or simultaneously with the cross-
intron interactions in each stage of the assembly (Figure 1.5, right column). Indeed, the 
U1 and U2 snRNP-containing exon-defined A complexes have been observed for several 
exons (Figure 1.5; A-like) (House and Lynch, 2006; Sharma et al., 2008). In addition, 
some exon-definition complexes have been shown to contain the tri-snRNP and the exon-
bound tri-snRNP can directly interact with the upstream 5’ ss to assemble the B complex 
across the intron (Figure 1.5; B-like) (Schneider et al., 2010b). However, despite the 
characterization of some exon-defined complexes, it is still unknown exactly what 
interactions of the RNA and protein components are involved in building the exon-
defined complex, and the connection or conversion of exon-defined to intron-defined 
complexes. 
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Figure 1.5 Exon-definition interactions along the spliceosome assembly pathway. 
Left, the canonical intron-defined orientation of spliceosome; right, the exon-defined 
version of each step. The cross-exon interactions can occur in any spliceosome 
complexes and then convert into the cross-intron interactions. The figure is adapted from 
(House and Lynch, 2008). 
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1.4 Regulation of alternative splicing by controlling splice site recognition   
         The best-studied mechanisms of alternative splicing regulation involve controlling 
the splice site recognition by regulating the association of the U1 snRNP, U2AF and the 
U2 snRNP with the 5’ and 3’ splice site, respectively (Black, 2003; Matlin et al., 2005). 
SR (Ser-Arg) proteins typically bind to an ESE and enhance the association of the 
spliceosome components to the splice sites flanking the regulated exon (Figure 1.6A) 
(Black, 2003). Moreover, ESEs are though to recruit SR proteins to establish a network 
of protein-protein interactions across the exon, thereby bridging U2 and U1 and 
stabilizing the exon-definied complex (Hoffman and Grabowski, 1992; Reed, 2000). The 
ESE-stabilized cross-exon interactions are then converted into cross-intron interactions to 
enhance the inclusion of the ESE-contianing exon (Figure 1.6A). In contrast, hnRNP 
proteins typically bind to an ESS to sterically block the ability of the spliceosomal 
components to bind to the splice sites, which disrupts the exon-definition interactions and 
represses the use of the splice sites flanking the regulated exons (Eperon et al., 2000). As 
a result, the use of the splice sites of the upstream and downstream exon is increased to 
induce the exclusion of the regulated exon (Figure 1.6B). Moreover, hnRNP proteins can 
compete with the SR proteins for binding to an overlapping ESE/ESS element (Zahler et 
al., 2004). Thus, the competition between SR and hnRNP proteins for binding to the pre-
mRNA provides a combinatorial control in influencing the splice site choice. Although 
most of the splicing regulators are shown to effect the early spliceosome assembly steps, 
the later tri-snRNP recruitment steps for the B complex assembly or structural 
rearrangements for the C complex formation are also the potential points for regulating 
alternative splicing (House and Lynch, 2008). 
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Figure 1.6 Regulation of initial splice site recognition by splicing regulators. (A) SR 
proteins bound to ESEs (green) recruit the U1 snRNP, U2AF and the U2 snRNP to the 
splice sites flanking the regulated exon via protein-protein or protein-RNA interactions, 
which facilitates the assembly of spliceosome on the flanking introns. (B) HnRNPs 
bound to ESSs (red) inhibit the recognition of splice sites by sterically blocking SR 
protein or U2AF interaction with the substrate, which promotes the spliceosome to 
assemble on the splice sites of the upstream and downstream constitutive exons to induce 
the exclusion of the regulated exon. 
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1.5 CD45, a model gene for studying alternative splicing   
          The CD45 gene encodes transmembrane protein tyrosine phosphatase, which is one 
of the most abundance proteins expressed on all hematopoetic cells and serves as an 
excellent model system for studying the signal-induced alternative splicing. The CD45 
gene contains 33 exons, in which exon 4, 5 and 6 are variably skipped (Figure 1.7A). The 
extent of the skipping of CD45 variable exons has been shown to be important for 
modulating T-cell receptor signaling and immune responses (Hermiston et al., 2002). 
Misregulation of alternative splicing of the CD45 gene increased susceptibility to a 
number of autoimmune diseases and viral infections (Dawes et al., 2006; Lynch, 2004; 
Tackenberg et al., 2003).  To elucidate the molecular mechanisms of alternative splicing 
of CD45 gene, the JSL1 cell line, which is derived from a human T-cell, was used for 
studying the alternative splicing of CD45 pre-mRNA. RT-PCR analysis of CD45 mRNA 
showed four dominant isoforms, including RABC, RBC, RC and RO isoform (Figure 
1.7B) (Lynch, 2004). The skipping of all three variable exon 4, 5 and 6 generates the RO 
isoform of CD45 mRNA, which encodes the PTPase lacking the extra-cellular domain 
and having reduced phosphatase activity (Figure 1.7C) (Xu and Weiss, 2002). 
Importantly, the most dominant isoform in JSL1 cells is RBC (Figure 1.7B; RBC with 
red color), which suggests that the exon 4, 5 and 6 are not regulated together and the 
skipping exon 4 is mostly independent of exon 5 and 6 (Figure 1.7A; red line).  
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Figure 1.7 CD45 exon 4, 5, and 6 are variably skipped in human JSL1 cells. (A) 
Schematic of the CD45 gene. The black and red lines indicate the splice sites used in the 
exclusion of the variable regions. (B) Representative phosphorimaging of an RT-PCR 
assay. Total RNA was harvested from a Jurkat-derived cell line, JSL1 cells. Primer for 
reverse transcription is complementary to a smell region within the exon 7. Forward 
primer is within the exon 3 and labeled with 32P, such that the following PCR products 
could be separated on a denaturing polyacrylamide gel and visualized by 
phosphorimager. Schematic of the RT-PCR products is shown in the left. (C) Domain 
structure of CD45 RABC and RO protein isoform. The variable exon 4, 5 and 6 encode a 
portion of the extracellular region of the protein tyrosine phosphatase (PTPase) that 
differs between RABC and RO isoform. Additionally, lacking the region encoded by 
these 3 variable exons reduces the phosphatase activity of the PTPase. 
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        Analysis of the auxiliary sequences within the CD45 variable exons identified a 60nt 
silencer element, ESS1, within each of the regulated exons (Figure 1.8A; ESS1) (Lynch 
and Weiss, 2001; Rothrock et al., 2003; Tong et al., 2005). Sequence analysis of the 
ESS1 element showed that it contains a CA-rich region. Mutating the CA-rich regions of 
the ESS1 sequence by introducing three point mutations generates the mESS1 sequence 
(Figure 1.8A; mESS).  
        To study the regulation of the skipping of CD45 exon 4, we made the 3-exon 
minigene in which exon 4 was flanked by the constitutive globin exons. The exon 4 of 
the 3-exon minigene contains either the ESS1 or mESS sequence (Figure 1.8B).  When 
the wild type CD45 minigene was stably integrated in JSL1 cells, PT-PCR analysis 
showed that approximately 4% of the minigene mRNA contains exon 4 (Figure 1.8C, left 
lane). Thus, the 3-exon minigene system recapitulates the skipping of CD45 exon 4 
(Lynch and Weiss, 2001). By contrast, when the CD45 minigene contains the mESS 
sequence, the inclusion of exon 4 is increased (Figure 1.8C, right lane). It indicates that 
the three point mutations within the ESS1 element disrupt its splicing silencing activity. 
Additionally, RNA affinity purification showed that hnRNP L is the most dominant 
protein associated with the ESS1 but not mESS1 RNA (Figure 1.8D). Therefore, we 
conclude that hnRNP L is the master regulator for inducing the skipping of CD45 exon 4 
by binding to ESS1 (Figure 1.8E) (Rothrock et al., 2005). 
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Figure 1.8 HnRNP L induces the skipping of CD45 exon 4 by binding to ESS1. (A) 
Sequence of ESS1 and mutated ESS1 (mESS). Nucleotides shown in bold text are the 
CA-rich region. Three point mutations in mESS1 relative to ESS1 are within the CA-rich 
region and indicated by underlined red text. (B) Schematic of the 3-exon minigene in 
which the CD45 variable exon 4 is flanked by the constitutive globin exons. The CD45 
minigene contains either ESS1 (red box) or mESS sequence (gray box) within exon 4. 
(C) RT-PCR analysis of the splicing of minigenes expressed in JSL1 cells using 
radiolabeled primer, as in Figure 1.7B. The 3-exon and 2-exon spliced RNA products are 
quantified by phosphorimager to calculate the percentage of the 3-exon RNA among total 
spliced RNA (% E4 inclusion). (D) Affinity purification of proteins associated with the 
ESS1 RNA. Silver-staining of proteins that were pulled down by the 5’-biotinylated 
ESS1, mESS or E14 RNAs from JSL1 nuclear extract. (E) The model of hnRNP L in 
repressing the inclusion of CD45 exon 4 by binding to ESS1. 
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1.6 HnRNP L induces the skipping of CD45 exon 4 by a novel mechanism 
         The dynamic assembly of the spliceosome suggests the regulation of splicing can 
occur at any of the intermediates along the spliceosome assembly pathway. Previous 
work used CD45 exon 4 as a model system to study the regulation of spliceosome 
assembly by hnRNP L. In the 3-exon minigene system, ESS1 represses the splicing of the 
introns flanking exon 4 to enhance the splicing of the intron flanked by the upstream and 
downstream constitute exon (Figure 1.9A; left). To eliminate complications from the 
upstream-downstream exon splicing pathway, the upstream exon was removed to 
generate the 2-exon pre-mRNA in which the exon 4 is flanked only by the downstream 
exon (Figure 1.9A; right). To characterize the mechanism of hnRNP L-mediated 
repression of exon 4 splicing, the splicing of the 2-exon ESS1-represssed substrate 
sequence is compared with a derepressed version in which the ESS1 is mutated to mESS 
(Figure 1.9B). The in vitro transcribed substrates were incubated with JSL1 nuclear 
extract to reconstitute the in vitro splicing reactions (Figure 1.9C). RT-PCR analysis of 
the RNA in vitro splicing reactions showed that in comparison to the derepressed 
substrate, ESS1 within the repressed substrate represses the splicing of the downstream 
intron (Figure 1.9D). Therefore, the splicing of the 2-exon pre-mRNA recapitulates the 
ESS1-mediated splicing repression of the 3-exon pre-mRNA as described in panel A 
(House and Lynch, 2006). 
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Figure 1.9 Recapitulation of ESS1-regulated splicing of CD45 exon 4 in vitro. (A) 
Comparison of the splicing regulation bewteen the 3-exon and 2-exon pre-mRNA. In the 
3-exon pre-mRNA, splicing occurs not only on the introns flanking exon 4 but also on the 
intron between upstream and downstream exon. In the 2-exon pre-mRNA, splicing and 
spliceosome assembly is limited into the intron downstream of exon 4. (B) Schematic of 
splicing substrates. The repressed (R) construct contains the wildtype ESS1 elements (red 
box) within exon 4. The derepressed substrate (D) contains the mutated ESS1 in which 
three point mutations abolish its association with hnRNP L binding and silencing activity 
(dark gray box) (also see chapter 6.1). (C) Schematic of the in vitro splicing assay. The in 
vitro transcribed RNA substrates were incubated with JSL1 nuclear extract under splicing 
conditions followed by the total RNA extraction for RT-PCR analysis. (D) RT-PCR 
analysis of the splicing reactions using radiolabeled primer, as in Figure 1.7B. Here, pre-
mRNA and spliced RNA are detected and quantified by phosphorimager to calculate the 
percentage of spliced RNA among total non-spliced and spliced RNA (% splicing). 
 
 19 
         The nuclear extract contains U1, U2, U4, U5 and U6 snRNP, which can be 
assembled on the pre-mRNA in a stepwise way to form different spliceosome 
intermediate complexes for splicing catalysis. To determine the spliceosome assembly 
steps that are altered by binding of hnRNP L to ESS1, spliceosome assembly reactions 
were reconstituted with nuclear extract depleted of different snRNPs. To induce the 
cleavage of snRNA, the oligonucleotides that are complementary to the internal region of 
the snRNAs were incubated with nuclear extract in the presence of RNase H (Figure 
1.10A). Primer extension analysis of the oligo-treated extract showed that the snRNAs 
are efficiently cleaved by the oligo-directed RNase H cleavage (Figure 1.10B). In the 
spliceosome assembly assays, the repressed or derepressed substrates were radio-labeled 
so that the complexes assembled on the substrates can be visualized in a native gel by 
phosphorimager (Figure 1.10C). Resolution of splicing reactions containing repressed 
and derepressed substrate in a native gel resulted in two and three super-shifted bands, 
respectively (Figure 1.10D; Total). The identities of the complexes within these bands 
were based on their migration in a native gel and their dependence on the individual 
snRNPs. The middle band is assigned to be the U1-and-U2-containing A complex 
because the middle band was greatly reduced in the absence of the U1 or U2 snRNP 
(Figure 1.10D; -U1 and -U2). The top band is assigned to be the U5.U6/U4-tri-snRNP-
containing B complex based on the fact that inactivation of U6 snRNP abolishes the top 
band (Figure 1.10D; -U6). Therefore, the progression from the A to B complex is blocked 
on the repressed substrate.  
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Figure 1.10 ESS1 represses the progression from the spliceosomal A to B complex. 
(A) Schematic of the oligonucleotide-directed cleavage of snRNAs in nuclear extract 
(NE). NE was incubated oligonucleotides that are complementary to U snRNAs to induce 
their cleavage by RNase H in NE. (B) Analysis of the efficiency of the cleavage of U 
snRNAs. RNAs extracted from H2O-treated NE (Total) or oligo-treated NE (-U1, -U2, 
and -U6) were analyzed by primer extension to detect the full-length and cleaved U 
snRNAs. (C) Schematic of the in vitro spliceosome assembly assay. The 32P-labeled 
RNA substrates were incubated with the indicated nuclear extracts followed by native 
acrylamide gel electrophoresis. (D) Representative phosphorimaging of the spliceosome 
assembly assay. The 32P-labeled R and D substrate, as in Figure 1.9B, were incubated in 
total splicing-competent NE (Total), or NE depleted of U1, U2 or U6 snRNP. 
Comigrating H and E complexes (H/E), A and B complexes are labeled.  
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         Combined the results from the in vitro splicing and spliceosome assembly assays, 
we provide the model in which hnRNP L represses the progression from the A to B 
complex to repress the splicing of CD45 exon 4. By contrast, mutating ESS1 to disrupt its 
association with hnRNP L allows the recruitment of the tri-snRNP into the A complex to 
form the B complex, which is then converted to C complex for the catalysis of splicing 
(Figure 1.11) (House and Lynch, 2006). 
 
         
Figure 1.11 Model for hnRNP L function in blocking the later spliceosome assembly 
steps to repress the splicing of CD45 exon 4. Binding of hnRNP L to ESS1 blocks the 
progression from the A to B complex, which results in repressing the splicing of the 
intron downstream of CD45 exon 4. 
 
 
 
 
           Based on the 2-exon substrate, a model for alternative splicing of the 3-exon 
substrate was provided, in which hnRNP L interferes the B complex assembly on the 
downstream intron to promote the splicing of the intron between upstream and 
downstream constitutive exon. (Figure 1.12A) (House and Lynch, 2008). This is a novel 
mechanism in that typical hnRNP proteins bind to ESS to block the E complex formation 
by sterically interfering with U1 snRNP binding at the 5’ splice site such that lower 
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affinities for U1 snRNP binding reduces the use of the 5’ ss (Figure 1.12B) (Eperon et al., 
2000). The fact that hnRNP L does not affect the A complex formation indicates that 
hnRNP L does not affect the initial recognition of the 5’ ss by U1 snRNP.  Instead, 
hnRNP L blocks the steps after U1 binding to repress the use of the 5’ ss of the ESS1-
containing exon. Together, the in vitro splicing and spliceosome assembly assays 
demonstrate that the later spliceosome assembly steps are the novel regulation points for 
hnRNP L in inducing the skipping of CD45 exon 4.  
 
                   
 
Figure 1.12 The assembly steps after U1 binding are novel points for regulating 
alternative splicing. (A) The 3-exon pre-mRNA model of hnRNP L-regulated 
alternative splicing in which U1 snRNP binding is not blocked. (B) The mechanism of 
other hnRNPs, such as hnRNP A1, in mediating the exclusion of exon by interfering U1 
snRNP binding.  
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Chapter 2 
ESS1 induces novel interactions of both U1 snRNA and hnRNP A1 with the 3’ end 
of CD45 exon 4 
 
        To regulate alternative splicing, most of the splicing regulators have been shown to 
sterically block the initial association of U1 snRNP, U2AF or U2 snRNP with splice sites 
(see chapter 1.4).  HnRNP L, the splicing regulator of CD45 exon 4, does not block 
association of U1 snRNP with the 5’splice site, but instead, it represses the steps after U1 
binding at the 5’ss to block the B complex formation (see chapter 1.5 and 1.6). However, 
it was unknown how hnRNP L perturbs the molecular interactions of the U1-5’ss 
complex to interfere the subsequent spliceosome assembly steps. Therefore, my initial 
goal was to elucidate how the binding of hnRNP L to ESS1 within CD45 exon 4 induces 
the aberrant molecular interactions between U1 snRNP and the pre-mRNA. 
 
2.1 Introduction: Motivation for characterizing U1 snRNP interactions within the 
hnRNP L-repressed spliceosome         
        Recently studies have shown that hnRNP L, PTB and RBM5 all function in 
repressing the B complex formation to induce the skipping of CD45 exon 4, Fas exon 6 
and N-src exon, respectively (Bonnal et al., 2008; House and Lynch, 2006; Sharma et al., 
2008). Although both of RBM5 and PTB have been shown to block the conversion from 
the cross-exon to cross-intron complex to repress the B complex formation, it is unknown 
exactly which spliceosome interactions are altered to repress the spliceosome assembly 
and induce the skipping of exons.  
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         Tim Nilsen’s group identified the other splicing silencer elements that can reduce 
the rate of splicing at the proximal strong 5’ splice site to promote the use of the distal 
weak 5’ ss for splicing (Figure 2.1A; compare black with blue line) (Yu et al., 2008). The 
splicing silencers do not alter the affinity of U1 binding at the 5’ ss, but instead, the 
splicing silencers perturb the molecular interactions of the U1 snRNP-5’ss complex 
(Figure 2.1A; compare the hexagon with the circle U1). Thus, the molecular interactions 
between U1 snRNP and the 5’ss are potential regulation points for alternative splicing. 
Here, I hypothesize that on the repressed RNA, the binding of hnRNP L to ESS1 also 
alters the U1-5’ss complex, which blocks the subsequent transition from the A to B 
complex and represses the splicing of CD45 exon. By contrast, on the derepressed RNA, 
U1 snRNP presumably binds in a canonical way that allows the assembly of the B 
complex and the subsequent catalysis (Figure 2.1B; compare repressed with derepressed). 
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Figure 2.1 Splicing silencers that shift the use of the 5’ splice site perturb the 
molecular interactions of the U1 snRNP-5’ss complex. (A) On the hypothetical RNA, 
the proximal strong 5’ splice site (5’ ss in blue text) is located downstream of a weakened 
5’ splice site (5’ ss in black text). The splicing silencing elements (red box) that reduce 
the rate of splicing at the proximal 5’ ss promotes the use of the distal 5’ ss for splicing. 
The splicing silencers were shown to perturb the molecular interactions of U1 
snRNP/5’ss complex. Blue and black lines indicate the proximal and distal 5’ splice sites, 
respectively, that are paired with the 3’ splice site for splicing. The circle U1 and 
hexagon U1 indicate the canonical and altered U1 binding, respectively. Adapted in part 
from (Yu et al., 2008). (B) Hypothesis of hnRNP L function in altering the U1 snRNP 
interaction within the A complex on the repressed substrate to block its transition into B 
complex and repress the splicing catalysis of the downstream intron. 
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2.2 Enrichment of the hnRNP L-repressed and -derepressed A complex 
         In the spliceosome assembly assays as described in chapter 1.6, the A complex is 
stalled on the ESS1-repressed substrate whereas the A complex is progressed into B 
complex on the derepressed substrate. The differences of U1 snRNP binding within the 
repressed versus derepressed A complex would indicate the U1-5’ss interactions that are 
altered by hnRNP L. Because U6 snRNP also interacts with the 5’ss in the B complex 
(see Figure 1.4), I set to separate the B from A complex and then compare U1 snRNP 
binding at the 5’ ss within the repressed and derepressed A complex.  
        To isolate and enrich the A complex, spliceosome assembly reactions were 
fractionated by glycerol-gradient centrifugation (Hartmuth et al., 2004). Based primarily 
on the size, spliceosome complexes sediment into different glycerol gradients under high-
speed centrifugation (Figure 2.2A). The complexes across the top to bottom gradient 
fractions were analyzed by native gel electrophoresis.  This showed that the A complex is 
enriched in the middle (M) fractions whereas the B complex is fractionated into the later 
(L) fractions (Figure 2.2B; compare the M with L fractions). Thus, for the derepressed 
complexes, the A complex is separated from the B complex and enriched in the middle 
fractions. It seems that higher levels of the E complexes co-sediment with the repressed- 
than with the derepressed-A complex in the M fractions. The levels of the E complex are 
variable among different sets of experiments so that I do not conclude that the 
progression from the E to A complex is blocked on the repressed substrate. Moreover, the 
variable levels of E complexes do not interfere the subsequent analysis as shown in the 
following chapters. Since the A complex is the most dominant complex in M fractions, 
the M fractions were collected for further analysis of U1 snRNP binding at the 5’ss. 
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Figure 2.2 Sedimentation of the A complex into the middle fraction. (A) Schematic of 
glycerol gradient centrifugation of the spliceosome assembly reactions. The spliceosome 
assembly reactions containing 2 pmol RNA substrates were layered on the glycerol 
gradient and then centrifuged at 45000 rpm for 3 hours. The gradient fractions were 
collected from top to bottom into 21 fractions. (B) Native gel electrophoresis of the 
gradient fractions. The complexes in gradient fractions were resolved in a native gel and 
analyzed by phosphorimager. The early (E), middle (M) and later (L) fractions were 
enriched for the H/E, A and B complex, respectively, for the derepressed substrate. 
Identifies of the complexes were primarily based on their migration in the native gel. 
 
 
 28 
2.3 HnRNP L induces a novel pairing interaction between the U1 snRNA and the 3’ 
end of CD45 exon 4 
           Along the splicesome assembly pathway, U1 snRNP binding at the 5’ splice site in 
the A complex proceeds progression into the B complex (Figure 1.4). The binding of U1 
snRNP at the 5’ splice site involves both of RNA-RNA and protein-RNA interactions. U1 
snRNP consists of U1 snRNA, seven Sm proteins, U1C, U1A, U1-70K and other minor 
protein components (Figure 2.3A).  The canonical base-paring interactions between the 
5’ end of U1 snRNA and the 5’ splice site involve 3 to 8 base-pairs that are typically not 
fully complementary (Figure 2.3A; pairing of the yellow box in U1 with the 5’ ss). The 
base-pairing interactions have critical roles in the recognition of the 5’ splice site 
(Guthrie and Patterson, 1988; Ruby and Abelson, 1988; Zhuang and Weiner, 1986).  
Recent crystal structural analysis of U1 snRNP showed that the zinc-finger domain of 
U1C binds across the RNA duplex at the 5’ss, which has been implicated in stabilizing 
the base-pairing interactions at the 5’ ss (Pomeranz Krummel et al., 2009).  
          To analyze the base-pairing interactions in the A complex, I incubated the pooled 
middle fractions with AMT-psoralen to induce the crosslinks of the base-paired regions 
upon UV-light irradiation. Site of crosslinks around the 5’ splice sites were then 
visualized as psoralen/UV-dependent stops in a primer extension reaction using primer 
that is complementary to the downstream region of the 5’ ss (Figure 2.3B).  
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Figure 2.3 Interrogation of base-pairing interactions on the pre-mRNA substrate by 
psoralen crosslinking assays. (A) Schematic of RNA-RNA and RNA-protein 
interactions of U1 snRNP binding at the 5’ splice site. (B) Schematic of primer extension 
analysis of the psoralen-crosslinked RNAs. AMT-psoralen was added into the colleted 
middle fractions from glycerol gradient centrifugation of spliceosome assembly reactions 
as in Figure 2.2. AMT-psoralen can intercalate between base-paired regions of RNAs. 
Upon UV-light irradiation, it forms the covalent bonds with the nearby RNA regions. To 
detect the crosslinked sites, the RNAs were extracted followed by primer extension, in 
which the reverse transcription stops at the crosslinked sites. 
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         Besides analyzing the 5’ ss by R2 primer, the psoralen-induced crosslinks around 
the branch point sites (BPSs) of exon 4 and AdML exon were also interrogated using the 
R1 and R3 primer (Figure 2.4A). Primer extension analysis of the psoralen-crosslinked 
RNAs did not detect any differences of the croslinking patterns around BPSs on 
repressed versus derepressed substrate (Figure 2.4B; R1 and R3). Moreover, the patterns 
of the crosslinking around the 5’ss are similar between the repressed and derepressed 
RNA (Figure 2.4C; 5’ss). Surprisingly, there is a crosslink upstream of the 5’ ss in the 
repressed but not derepressed substrate (Figure 2.4C; red arrow). By running the 
sequencing reactions with primer R2 in parallel with the crosslinking analysis around the 
5’ ss, the repression-dependent crosslink is mapped to a cytosine residue 15 nucleotides 
upstream of the 5’ss (Figure 2.4D; C-15). Therefore, the psoralen-crosslinking assays 
identified a repression-dependent C-15 crosslink at the 3’ end of  exon 4.  
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Figure 2.4 An ESS1-dependent crosslink is mapped to the cytosine residue, which is 
15-nucleotide upstream of the 5’ splice site. (A) Schematic of the repressed substrate 
showing relative location of primers (R1-3) used for mapping psoralen-crosslinked sites 
on branch point sites from exon 4 and AdML exon (E4-BPS and AdML-BPS), and the 5’ 
ss from exon 4. (B) Primer extension analysis of psoralen-induced crosslinked sites of the 
complexes in the middle fraction using primer R1 and R3 as described in Figure 2.3B. 
(C) Primer extension analysis using primer R2 as in panel B. The red arrow points at the 
repression-specific crosslink. (D) Primer extension analysis of psoralen-crosslinked 
reactions (PE) or a sequencing reaction with ddNTPs (Sequ.) using primer R2. Locations 
of several crosslinks are shown, including the 5’ ss and the primary differential crosslink 
(C-15). 
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        To determine whether U1 snRNP is involved in the crosslink at C-15, I performed 
the psoralen-crosslinking with the complexes assembled in nuclear extract depleted of U1 
snRNP. The fact that the crosslinks at the 5’ ss are reduced after depleting U1 snRNP 
indicates U1 snRNP is vacated from the 5’ss. Moreover, in the absence of U1 but not U2 
snRNP, the C-15 crosslink on the repressed substrate is significantly disrupted (Figure 
2.5A). To more rigorously analyze the RNA crosslinked to the C-15 region, the 
complexes assembled on the 32P-labeled 5’ss RNA fragments are psoralen-crosslinked 
followed by denaturing gel electrophoresis (Figure 2.5B; panel C). While most of the 5’ 
ss RNA fragments were not crosslinked, a small portion of the 5’ ss RNA is crosslinked 
to form a supershifted band (Figure 2.5C; black arrow). Additionally, in the absence of 
U1 snRNP, the supershifted band is reduced. To further demonstrate that the psoralen-
induced supershifted band contains the U1 snRNA, I performed the oligo-directed 
cleavage of the psoralen-crosslinked RNAs (Figure 2.5B; panel D). Using the oligos to 
cleave the internal region of the U1 snRNA, the intensity of the supershifted band is 
reduced with the concurrent generation of two new bands, which are supposed to be the 
cleaved RNAs (Figure 2.5D; U1internal). When the 5’ end of the U1 snRNA is cleaved, the 
supershifted band is not changed (Figure 2.5D; U15’end). This indicates that the internal 
region but not the 5’ end of the U1 snRNA is involved in the psoralen-induced supershift 
of the 5’ ss RNA fragment.  
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Figure 2.5 The internal region of the U1 snRNA is crosslinked to the 3’ end of exon 
4. (A) Primer extension analysis of psoralen-crosslinked reactions containing the 5’ ss 
RNA fragment (see panel B) incubated with the splicing-competent nuclear extract 
(mock), or extract depleted of U1 or U2 (-U1 or -U2). (B) The schematic of supershift 
assays. The 5’ ss RNA fragment encompasses the sequence spanning -45 to +76 relative 
to the 5’ ss was incubated with NE followed by psoralen crosslinking. The RNA 
extracted from the psoralen crosslinked reactions was directly analyzed by denature gel 
as in panel C or treated with oligos to induce its cleavage by RNase H followed by 
denature gel analysis as in panel D. (C) Supershift analysis of the poralen-crosslinked 5’ 
ss RNA fragment incubated with the indicated NE. The arrow points at the supershifted 
band that is dependent on U1. (D) Supershift analysis of the psoralen crosslinked RNAs 
that were cleaved by oligo-directed RNase H cleavage. The sequences of the 
oligonucleotides are listed in Chapter 6. 
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2.4 The extended U1 interaction involves the 3’ portion of helix H in U1  
         To investigate the region of the U1 snRNA that is involved in the novel pairing 
interaction with CD45 exon 4, I examined the sequence and secondary structure of the 
U1 snRNA. The internal region of U1 snRNA includes four stem loops and one helix H 
located between the stem loop I and III (Figure 2.6A; U1 snRNA). Several studies have 
shown that interactions of the 5’ end of U1 snRNA with the 5’ ss can extend into the 5’ 
stem of helix H in U1 (Abad et al., 2008; Kaida et al., 2010). This indicates that the two 
stems of helix H do not always keep paired, but instead, it could unwind to allow the 
extended U1 interactions with the substrate (Figure 2.6A; unwinding of U1 snRNA). 
Thus, while the 5’end of U1 snRNA interacts with the 5’ ss, the 3’ stem of helix H of U1 
snRNA could potentially make the extended contacts with the C-15 region of exon 4. 
Sequence analysis of helix H region of U1 snRNA revealed that the GCAU sequence in 
the 3’ stem of helix H could potentially base-pair with the GUGC sequence with the C-15 
region within exon 4 (Figure 2.6B; purple sequence of U1). Moreover, the extended U1 
base-pairing interaction at the C-15 region could co-exist with the canonical U1 
interaction at the 5’ ss (Figure 2.6B; yellow box of U1).  
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Figure 2.6 Model of base-pairing interactions between the 3’ portion of helix H in 
U1 with the 3’ end of exon 4. (A) Schematic of model of unwinding helix H in U1 for 
making the extended U1 interactions. (B) The putative U1 sequences for making the 
extended interaction with the 3’ end of exon and the canonical interaction with the 5’ ss. 
The helix H region in U1 is shown in purple sequence. The sequence of the 5’ end of U1 
is shaded with the yellow color. The sequence of the C-15 region within exon 4 is inside 
the red box.  
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         To support this model, I created several mutations within the C-15 region to 
potentially disrupt or enhance the putative extended U1 interaction. Previously, we have 
shown that mutating residues -24 to -13 reduces the skipping of exon 4 in cells although 
it has less effect than mutating ESS1 (Lynch and Weiss, 2001). Importantly, this 
functionally-defective mutation in the -24 to -13 region could reduce the extended U1 
interaction (Figure 2.7A; QC9). I also mutated four nucleotides downstream of C-15 to 
allow the putative region that is involved in the extended U1 interaction to become fully 
complementary (Figure 2.7A; U1up). Consistent with the predicted interaction model, the 
QC9 mutation greatly reduces the C-15 crosslink, whereas the U1up mutation enhances it 
(Figure 2.7B). Additionally, the QC9 mutation within the C-15 region also reduces the 
supershifted band that is dependent on U1 (Figure 2.7C). Notably, neither of these 
mutations significantly impacts the crosslinks at the 5’ss, which indicates that hnRNP L-
induced association of the internal region in U1 with the exonic region does not interfere 
base-pairing of the 5' end of U1 with the 5’ ss. 
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Figure 2.7 Mutant sequences at the 3’ end of exon 4 that potentially alter the 
putative extended U1 base-pairing interaction. (A) Schematic of the potential changes 
of the U1 base-pairing interaction by creating QC9 and U1up mutation into the C-15 
region. The nucleotides that differ from wildtype exon 4 are shown in red color. (B) 
Primer extension analysis of the psoralen-crosslinked reactions containing the repressed 
substrates with the wildtype or mutant sequences (Q and U) in the C-15 region. (C) 
Supershift analysis of the poralen-crosslinked 5’ ss RNA fragment containing wildtype or 
mutant QC9 sequence in the C-15 region. 
 
 
        As a complementary approach, I attempted to map the psoralen-induced crosslinks 
within the U1 snRNA that are dependent on the association of U1 with the 3’ end of exon 
4. To eliminate the background crosslink patterns from the free U1 snRNP, I set to 
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analyze the purified U1-5’ ss complexes. To permit purification, the hairpin sequence 
binding site for the MS2 viral coat protein was inserted into the 3’ end of the 5’ ss RNA 
(Jurica et al., 2002; Zhou et al., 2002). The MS2MBP-tagged 5’ ss RNA is incubated with 
nuclear extract followed by affinity-purification using amylose resin (Figure 2.8A). The 
primer that targets to the SLII in U1 was used for interrogating the psoralen-induced 
crosslinks within the U1 snRNA in the purified U1-5’ ss complex (Figure 2.8B). This 
revealed that the crossslink at the 5’ helix H is reduced when the C-15 region contains the 
wild-type sequence (Figure 2.8C). This suggests that the interaction of 5’ stem with 3’ 
stem of helix H is reduced when the substrate contains the wildtype sequence for its 
interaction with the 3’ stem of helix H (Figure 2.8B; wildtype). By contrast, the helix H 
in U1 keeps in the helical form on the substrates when the extended U1 interaction with 
the C-15 region is disrupted (Figure 2.8B; Q mutation).   
        I also attempted to map the crosslinks within the 3’ stem of helix H in U1. However, 
the 3’ helix H in U1 is predicted to not only pair with the 3’ end of exon 4 but also with 
the 5’ helix H in U1 (Figure 2.8B). Thus, although I observed a strong the crosslink at 3’ 
helix H in U1 snRNA even in the absence of the 5’ss RNA substrate (data not shown), I 
cannot distinguish intra- versus inter-molecular interactions.  
          To further determine whether the unwinding of helix H of the U1 snRNA alters 
association of the U1 snRNP proteins with the U1 snRNA, I performed western blotting 
analysis of the purified U1-5’ ss complex. This showed that the levels of U1 snRNP 
proteins are not significantly changed by creating the QC9 mutation into the C-15 region 
of the 5’ ss RNA fragment (Figure 2.8D).  
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Figure 2.8 Disrupting association of the U1 snRNA with the 3’ end of exon 4 
increases the helical form of helix H in U1. (A) Schematic of MS2MBP purification of 
the U1-5’ss complexes. After incubating the MS2MBP-tagged 5’ss RNA with NE, the 
entire splicing reaction is immobilized onto the amylose beads followed by the steps of 
washing and elution. The 5’ss RNA fragment is the same as in Figure 2.5A. (B) 
Schematic of potential differences of the U1 helix H structure upon disrupting the 
extended U1 interaction by the QC9 mutation. Primer that targets to SLII in U1 was used 
for interrogating the psoralen-crosslinked sites of the U1 snRNA in the purified U1-5’ ss 
complex. (C) Analysis of psoralen-crosslinked U1 snRNA. “Readthrough” and “5’ helix 
H” are the products from the reverse-transcription of the non-crosslinked U1 snRNA or 
U1 RNA crosslined at helix H, respectively.  % crosslinking is calculated from the ratio 
of 5’ helix H xlink to readthrough. (D) Western blot analysis of the purified complexes 
assembled on the 5’ ss RNA containing either wild-type (W) or mutant (Q) C-15 region. 
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2.5 The extended U1 interaction alters the structural flexibility of the U1 snRNA  
          The effects of the extended U1 interactions on the conformational changes of U1 
snRNP in the purified U1-5’ ss complex were further investigated. I used the strategy of 
RNA selective 2’-hydroxyl acylation analyzed by primer extension (SHAPE) to map the 
regions of the U1 RNA that displays differential flexibility upon disrupting the extended 
U1 interaction (Mortimer and Weeks, 2009).    
         After MS2-MBP affinity selection of the assembled complexes from the 
spliceosome assembly reactions (see the procedure in Figure 2.8A), the purified 
complexes were treated with benzoyl cyanide (BzCN) followed by the RNA extraction 
and primer extension (Figure 2.9A). The hydroxyl-selective electrophile of BzCN reacts 
with the flexible nucleotides to form the 2’O-adduct nucleotide (Figure 2.9B). By 
contrast, base-paired or otherwise conformationally constrained nucleotides are 
unreactive. Primer extension analysis of the 2’O-adduct formation in the U1 snRNA 
showed that the 5’ helix H and stem loop I regions are more accessible on the wildtype 
than QC9 mutant substrate (Figure 2.9C). The fact that the 5’ helix H is more flexible on 
wildtype substrate is consistent with the model in which the pairing interaction within the 
5’ helix H in U1 is disrupted to allow the formation of the extended U1 interactions in the 
C-15 region on the wildtype substrate (Figure 2.8B). 
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Figure 2.9 SHAPE analysis of the U1 snRNA in the absence or presence of the 
extended U1 interaction. (A) The schematic of SHAPE analysis of the MS2MBP-
purified spliceosome. (B)The mechanism of RNA SHAPE chemistry with BzCN. BzCN 
reacts with 2’-hydroxyl groups at conformationally flexible positions to form a 2’-O-
adduct. (C) SHAPE analysis of the purified U1-5’ ss RNA complexes. Primer extension 
analysis of BzCN-treated purified U1-5’ss complexes. Arrows indicate the regions of U1 
snRNA that show differential accessibility for reacting with BzCN in the wildtype versus 
QC9 mutant complexes. 
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2.6 HnRNP L recruits hnRNP A1 to induce association of the U1 snRNA with the 3’ 
end of exon 4 
           In the CD45 exon 4, the location of the ESS1 is 110 nt upstream of the 5’ splice 
site (Figure 2.1A). Other proteins that associate with the region nearby the C-15 region 
could mediate the ESS1/hnRNP L-induced extended U1 interaction. To investigate the 
presence of proteins in the vicinity of the U1-exon interaction, I synthesized a site-
specific-labeled repressed or derepressed substrate in which the G-16 nucleotide is 
radiolabeled. Spliceosome complexes assembled on these substrates were crosslinked 
with shortwave UV light followed by RNase digestion (Figure 2.10A). I observed two 
proteins, a ~65 and ~35 kDa protein, that are crosslinked to the radiolabled G-16 in the 
repressed but not derepressed substrate (Figure 2.10B). Using antibodies that are against 
hnRNP L and A1 specifically immunoprecipitated the radiolabeled 65 and 35 kD protein, 
respectively, from the UV-crosslinked complexes (Figure 2.10C). As hnRNP A1 is 
specifically associated with the C-15 region on the repressed but not derepressed 
substrate, hnRNP A1 could possibly mediate the ESS1/hnRNP L-induced extended U1 
interactions. 
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Figure 2.10 HnRNP A1 and L are crosslinked to the G-16 nucleotide in an ESS1-
dependent manner. (A) Schematic of UV crosslinking assay. The site-specific labeled 
RNA containing a radiolabeled phosphate at G-16 is incubated with NE followed by 
UV254-irradiation, RNase digestion and SDS-page electrophoresis as in panel B. The 
crosslinked and RNase-digested reactions were also incubated with antibodies to 
immunoprecipiate the crosslinked proteins as in panel C. (B) Analysis of proteins 
crosslinked to G-16 nucleotide of the R or D substrates in a SDS-PAGE by 
phosphorimaging. (C) Analysis of the immunoprecipitated proteins in a SDS-PAGE by 
phosphorimaging. 
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         Besides hnRNP A1 and L, there is a variable ~75 kDa band that is also crosslinked 
to G-16 (Figure 2.11A). Additionally, the binding of this 75 kDa protein is enhanced 
when U1 snRNP is depleted from nuclear extract (Figure 2.11A; -U1). This suggests that 
when U1 snRNP is vacated from the 5’ splice site, it allows the binding of the 75 kDa 
protein into the C-15 region. Immunoprecipitation of UV crosslinked reactions using 
hnRNP M antibody showed that the 75 kDa protein is hnRNP M, a RNA-binding protein 
that prefers the poly-G or poly-U sequences (Figure 2.11B) (Huelga et al., 2012). 
Sequence analysis of the C-15 region showed that there is a stretch of poly U sequence 
downstream of C-15 (Figure 2.6B). However, further studies showed that the levels of 
hnRNP M in the C-15 region are not changed when the extended U1 interaction is 
disrupted (Figure 2.12B and C) or during the splicing repression or activation (Figure 
3.3C and D). Thus, hnRNP M is considered to associate with the C-15 region when U1 
snRNP is vacated from the C-15 region but not to be involved in inducing the extended 
U1 interactions or hnRNP L-mediated splicing repression.   
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Figure 2.11 HnRNP M is crosslinked to the G-16 nucleotide when U1 snRNP is 
vacated from the 3’ end of exon 4. (A) Analysis of proteins crosslinked to G-16 
nucleotide of the R or D substrate in mock or U1-depleted NE. (B) Immunoprecipitation 
of the protein that was crosslinked to G-16 on the R substrate using hnRNP M antibody. 
     
          It has been shown that hnRNP L prefers the CA-rich RNA sequence for binding 
(Hui et al., 2005) whereas the consensus of hnRNP A1 binding site is UAGGGA/U (Burd 
and Dreyfuss, 1994). Analysis of the sequence around the G-16 nucleotide reveals that a 
UAGUG sequence element spanning from nucleotides -20 to -16 could be a weak hnRNP 
A1 binding site. (Figure 2.12A; UAGUG in blue box). To investigate whether hnRNP A1 
mediates the extended U1 interactions at the C-15 region, I mutated the UAGUG 
sequence by replacing A by C nucleotide, which is predicted to disrupt the hnRNP A1 
binding, but not alter the putative basepairing with the U1 snRNA (Figure 2.12A). 
Strikingly, this mutation not only abolishes crosslinking of hnRNP A1 to G-16 nucleotide 
(Figure 2.12B) but also reduces the C-15 crosslink and the U1-dependent supershifted-
band (Figure 2.12C and D). Thus, binding of hnRNP A1 at the 3’ end of exon 4 mediates 
the hnRNP L-induced extended pairing interactions of the U1 snRNA. 
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Figure 2.12 Binding of hnRNP A1 to G-16 is required for hnRNP L-induced 
extended U1 interaction in the C-15 region. (A) Schematic of the A-to-C mutation 
within the putative hnRNP A1 binding site (UAGUG in blue box) and the G-16 
containing the radiolabeled phosphate. (B) UV crosslinking as in Figure 2.11A with the 
substrate containing wildtype (W) or A-to-C mutant (A) C-15 region. (C) Primer 
extension analysis of psoralen-crosslinked sites with primer R2 as in figure 2.4. (D) 
Supershift analysis of the psoralen-crosslinked RNAs as in figure 2.5.  
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2.7 HnRNP A1 and the U1 snRNA associate cooperatively with the 3’ end of exon 4 
in an ESS1-dependent manner 
         As mentioned in chaper 2.6, the UAGUG in the C-15 region is not a conserved 
binding sequence for hnRNP A1. As this binding site is nearby the 5’ splice site, I set to 
investigate the correlation between the hnRNP A1 binding and the U1 snRNA association 
at the 3’ end of exon 4. In chapter 2.3, the QC9 and U1up mutation have been shown to 
disrupt and enhance the extended U1 interactions, respectively, on the repressed 
substrate. The substrates containing these mutations were radiolabeled at G-16 followed 
by UV-crosslinking analysis. It showed that crosslinking of hnRNP A1 to G-16 is 
reduced by the QC9 mutation, whereas it is not interfered by the U1up mutation (Figure 
2.13A). Additionally, in the absence of U1 but not U2 snRNP,  hnRNP A1 binding at G-
16 is abolished (Figure 2.14B). This demonstrates that U1 binding at the C-15 region 
enhances association of hnRNP A1 with the same region to mediate the extended U1 
interaction. Therefore, hnRNP A1 and the U1 snRNP associate cooperatively with the 3’ 
end of exon 4 in a manner that is dependent on the ESS1. 
                           
 
Figure 2.13 HnRNP A1 and U1 snRNA are cooperatively associated with the C-15 
region. (A) UV crosslinking as in Figure 2.11A with the indicated substrate. (B) UV 
crosslinking as in Figure 2.11A with the repressed substrate incubated with the mock, U1 
or U2-depleted NE.  
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2.8 The potential interactions between hnRNP L or A1 with the U1 snRNP      
           Although I have shown binding of hnRNP L and A1 in the ESS1 and C-15 region 
is correlated the extended U1 interaction (Figure 2.5 and 2.12), it is not known whether 
hnRNP L or A1 directly remodels the molecular interactions of U1 snRNP with the 
substrate. HnRNP A1 was shown to have both helix destabilizing and RNA annealing 
activities, such that hnRNP A1 promotes interconversion of RNA basepairing 
interactions (Grohman et al., 2013; Kumar and Wilson, 1990; Pontius and Berg, 1990). 
However, no specific substrate of hnRNP A1 RNA chaperon activity has yet been 
identified in the spliceosome. The direct interactions between hnRNP A1 and U1 snRNA 
might aid in inducing the extended U1 interaction with the substrate.  Previously, PTB 
has been shown to bind directly to U1 snRNA to potentially alter the interaction of U1 
snRNP with other spliceosome components (Sharma et al., 2011). To investigate the 
interactions between hnRNP proteins and the U1 snRNA, I analyzed the RNA 
components in the UV-crosslinked nuclear extracts that were immunoprecipitated by 
hnRNP L or LL-antibody (Figure 2.14A). It showed that there is no significant increased 
binding of L or LL protein with the U1 snRNA in a UV-dependent manner (Figure 
2.14B). Therefore, future work would be to investigate whether hnRNP L or A1 interacts 
with the protein components of U1 snRNP to remodel its binding at the region around the 
5’ ss. 
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Figure 2.14 HnRNP L and L-like may not directly interact with the U1 snRNA. (A) 
Immunoprecipitation of hnRNP L from UV-crosslinked nuclear extract. The UV 
crosslinked NE was incubated with antibodies to immunoprecipitate the crosslinked 
RNA-protein complexes. The RNA components in the immunopreciptated, crosslinked 
complexes were extracted and analyzed by primer extension. (B) Analysis of levels of U1 
and U2 snRNA by primer extension in hnRNP L or LL-antibody-precipitated UV-
crosslinked complexes. The levels of the precipitated hnRNP L or LL proteins were 
detected by western blot. Because the antibodies precipitated more hnRNP L or LL 
protein from the non-UV-treated reactions, only 1/3 of the precipitated complexes were 
used for both the primer extension and western blot analysis. 
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2.9 Discussion 
        Previously, binding of hnRNP L to ESS1 was shown to be required for repressing 
the progression from the A to B complex and splicing. In this chapter, ESS1/hnRNP L is 
demonstrated to induce the cooperative binding of hnRNP A1 and the U1 snRNA with 
the 3’ end of exon 4 within the hnRNP L-repressed A complex (Figure 2.15), which 
could potentially function in repressing spliceosome assembly and splicing catalysis. The 
pairing interaction between the 3’ portion of helix H in U1 with the C-15 region is 
demonstrated by a series of biochemical approaches including U1-oligo-directed 
cleavage of the psoralen-crosslinked 5’ ss RNA fragment (see chapter 2.3), psoralen-
crosslinking analysis of the C-15 region mutant substrate (see chapter 2.4), and SHAPE 
analysis of the U1-5’ss complex (see chapter 2.5). Moreover, western blot analysis of the 
U1-5’ss complex showed that unwinding helix H in U1 to form the extended interaction 
does not interfere with association of the U1 snRNP proteins (see chapter 2.4). UV 
crosslinking analysis of site-specific-labeled RNA revealed that hnRNP L recruits hnRNP 
A1 to induce the extended U1 pairing interaction (see chapter 2.6 and 2.7). Although it is 
possible that hnRNP L or A1 directly interact with the U1 snRNA to induce the extended 
pairing interaction, immuno-precipitating the UV-crosslinked U1 snRNP by hnRNP L 
antibody did not reveal the crosslinking of hnRNP L to the U1 snRNA (see chapter 2.8). 
Future work will be required to identify the protein-protein interactions that allow hnRNP 
L at the ESS1 or hnRNP A1 at the 3’ end of exon 4 to induce the extended conformation 
of U1 snRNP at the 5’ ss.  
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Figure 2.15 Model for recruitment of hnRNP A1 and the U1 snRNA to the 3’ end of 
exon 4 by hnRNP L. HnRNP L recruits hnRNP A1 to the C-15 region, which induces 
the extended U1 interaction with the 3’ end of exon 4 on the repressed substrate. By 
contrast, creating the QC9 and A-to-C mutations at the C-15 region or mutating ESS1 on 
the derepressed substrate disrupts association of hnRNP A1 and U1 snRNA with the 3’ 
end of exon 4. 
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Chapter 3 
HnRNP L recruits hnRNP A1 and the U1 snRNA to the 3’ end of exon 4 to induce 
the skipping of exon 4 
 
        In chapter 1, I showed that ESS1 represses the splicing of the downstream intron to 
induce the skipping of CD45 exon 4. In chapter 2, the exonic splicing silencer (ESS1) 
within CD45 exon 4 is shown to promote the extra interactions between U1 snRNP and 
the 3’ end of exon 4. Forcing aberrant spliceosome interactions has been demonstrated to 
alter splicing efficiency in other systems. However, it is unknown whether the ESS1-
induced U1 interaction at the 3’ end of exon 4 is required for ESS1 to induce the skipping 
of exon 4. The goal of this chapter is to elucidate whether the naturally occurring 
additional U1 interactions at the exonic region contribute to hnRNP L/ESS1-dependent 
splicing repression. 
  
3.1 Introduction: Forcing aberrant snRNP interactions with the pre-mRNA alters 
splicing efficiency 
         The spliceosome assembly processes involve a multitude of interactions between 
spliceosome components and the reactive regions of pre-mRNA, which ensure the 
fidelity of splice site selection (also see chapter 4.1). Growing evidence showed that the 
steps of the spliceosome assembly can proceed in both the forward and reverse directions 
(Tseng and Cheng, 2008). This reversibility suggests that modulating spliceosome 
interactions would alter the kinetic equilibrium between spliceosome assembly steps to 
affect splicing efficiency (Smith et al., 2008). Two well-characterized examples of kinetic 
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competition occur in the transition from U1 to U6 binding at the 5’ splice site and the 
transition from the first to second catalytic step (Figure 3.1). The group of Jon Staley 
demonstrated that hyperstabilization of the pairing interactions between the U1 snRNA 
and the 5’ ss represses the subsequent binding of U6 snRNP (Staley and Guthrie, 1999). 
Additionally, Charles Query’s group showed that hyperstabilization or destabilization of 
the pairing interactions between U6 snRNA and the 5’ ss modulates the equilibrium 
between the conformations of the first and second catalytic step (Konarska et al., 2006). 
Differential favoring of one assembly pathway over another can lead to changes of the 
ratio of spliced product to pre-mRNA. Therefore, the dynamic RNA-RNA interactions 
are potential points for modulating splicing efficiency and directing splice site choice. 
            
Figure 3.1 The spliceosome assembly steps proceed in both the forward and reverse 
directions. (A) Schematic of transition between U1 and U6 snRNP binding at the 5’ ss. 
Mutating the sequence of the 5’ splice site to extended the pairing interactions between 
U1 snRNA and the 5’ ss hyperstabilizes U1 binding and represses the subsequent U6 
binding. Adapted in part from Molecular Biology of the Cell, 4th edition. (B) Schematic 
of transition between the first and second catalytic step. Hyperstabilization and 
destabilization of the 5’ss-U6 duplex favors the conformation of the first and second step, 
respectively. Adapted in part from other figures (Konarska et al., 2006). 
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3.2 Association of hnRNP A1 and U1 with 3’ end of exon 4 is required for 
ESS1/hnRNP L-mediated splicing repression in vitro and in cells 
          To investigate whether the extraneous U1 snRNP association with the exonic 
region also functions in altering splicing efficiency, the in vitro splicing assays were 
performed with the substrates containing mutations that disrupt binding of A1 and U1 at 
the C-15 region (Figure 3.2A and B). Remarkably, the splicing of the 2-exon-pre-mRNA 
and the inclusion of CD45 exon 4 on the 3-exon pre-mRNA are increased by ~2 fold 
when the C-15 region contains the Q or A mutation.  
 
          
Figure 3.2 HnRNP A1 and U1 interactions at the C-15 region are required for 
ESS1-mediated splicing repression in vitro. (A) Top, schematic of the 2-exon 
repressed substrate containing wildtype or mutated C-15 region (Q, A, U as defined in 
Figure 2.7A). Bottom, RT-PCR analysis of the in vitro splicing assay using radiolabeled 
primers, as in Figure 1.9D. (B) Top, schematic of 3-exon repressed substrate containing 
wildtype or mutated C-15 region or derepressed substrate. Bottom, RT-PCR analysis of  
the in vitro splicing reactions using radio-labeled primers.  
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        To further investigate the importance of the molecular interactions at the 3’end of 
exon 4 in splicing repression, I designed an anti-sense 2’O-methyl oligonucleotide that is 
complementary to the sequences spanning -24 to -13 of exon 4 to block the association of 
hnRNP A1 and the U1 snRNA with the C-15 region (Figure 3.3A; anti-E4). Pre-
incubating the anti-E4 oligo with the pre-mRNA substrate under splicing conditions 
abolishes the psoralen-induced C-15 crosslink and the UV-induced crosslinking of 
hnRNP A1 to G-16 nucleotide (Figure 3.3B and C). Importantly, in the presence of anti-
E4 oligo, the increase in splicing is more for the repressesd versus derepressed substrate 
(Figure 3.3D). Therefore, binding of A1 and U1 at the C-15 region specifically mediates 
the splicing repression of the ESS1-repressed substrate but not depressed substrate.  
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Figure 3.3 Blocking association of hnRNP A1 and U1 with the 3’ end of exon 4 by an 
anti-sense oligo disrupts ESS1-medaited splicing repression. (A) Schematic of 2’O-
methyl anti-3’E4 oligo pairing with exon 4. (B) Primer extension analysis of psoralen-
crosslinked sites of complexes in the splicing reactions using indicated primers as in 
Figure 2.4. In the splicing reactions, the substrates were treated with (+) or without (-) the 
anti-3’E4 oligo followed by incubating in the NE. (C) UV crosslinking analysis as in 
Figure 2.11 in the presence (+) and absence (-) of the anti-3’E4 oligo. (D) In vitro 
splicing of the substrates that are pre-incubated with indicated concentration of the anti-
3’E4 oligo. 
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        Previously, binding of hnRNP L to ESS1 has been shown to repress the splicing of 
the upstream intron by blocking the progression from the A to B complex (Figure 3.4A 
and B). Notably, the anti-E4 oligo does not enhance the splicing of the upstream intron 
on the ESS1-repressed substrate (Figure 3.4C and D). This indicates that the mechanism 
by which ESS1 regulates spliceosome assembly and splicing repression of the upstream 
intron does not require the molecular interactions at the C-15 region.  
 
            
Figure 3.4 Blocking association of hnRNP A1 nd U1 with the 3’ end of exon 4 does 
not overcome the ESS1-mediated splicing repression on the upstream intron. (A) 
Schematic of the 2-exon substrates in which exon 4 is flanked by the upstream exon. (B) 
Spliceosome assembly assays as in Figure 1.10. (C) In vitro spilcing assays as in Figure 
3.2A. (D) In vitro splicing of the substrates that are pre-incubated with the indicated 
concentrations of the anti-3’E4 oligo. 
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        To investigate the effect of the association of hnRNP A1 and the U1 snRNA with 
exon 4 in cells, the 3-exon CD45 minigenes containing wildtype or mutated C-15 region 
were delivered into JSL1 cells (Figure 3.5A; top).  The 3-exon CD45 minigenes have 
been demonstrated to recapitulate the hnRNP L/ESS1-mediated skipping of exon 4 
(Figure 1.8). The QC9 and A-to-C mutations in the C-15 region reduce the skipping of 
CD45 exon 4 in cells (Figure 3.5A; bottom).  Moreover, knockdown of either hnRNP L 
or A1 results in a reduction in exon 4 skipping in the 3-exon pre-mRNA expressed from 
the minigene (Figure 3.5B and C). Notably, the U1up mutation that has been shown to 
increase the C-15 crosslink does not further repress the splicing of exon 4 either in vitro 
or in cells (Figure 3.2A and 3.5A). Our explanation is that the presence of ESS1 has 
already made the maximal splicing repression of exon 4. Moreover, other positive 
factors, such as SR protein, have been shown to function in enhancing exon 4 splicing. 
Further strengthening the aberrant U1 interaction by U mutation may not overcome the 
positive effects induced by these SR proteins such that U mutation cannot induce further 
repression beyond the silencing activity of ESS1. 
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Figure 3.5 Association of hnRNP A1 and U1 with the 3’end of exon 4 is required for 
ESS1- and hnRNP L-induced skipping of exon 4 in cells. (A) Top, schematic of the 
CD45 exon 4 minigene containing wildtype or mutated C-15 region. Bottom, RT-PCR 
analysis of the splicing of the indicated minigenes expressed in 293 cells. (B) 
Knockdown efficiency of hnRNP L and A1 for experiments in panel C. (C) RT-PCR 
analysis of the splicing of the wildtype exon 4 minigene expressed in 293 cells 
transfected with nothing (-), siRNAs to hnRNP L (si L), hnRNP A1 (si A1) or GFP as a 
control. 
 
 
 
 
 
 
 
 
 
 
 60 
3.3 MS2-tethering system for studying the silencer activity of hnRNP L  
         In chapter 3.2, I investigated the splicing silencing activity of hnRNP L through 
comparing the splicing efficiency of the substrate containing CD45 exon 4 ESS1 versus 
mESS. The three point mutations within the ESS1 element generate the mESS sequence 
and disrupt binding of hnRNP L. Although the most dominant protein that associates with 
the ESS1 element is hnRNP L, other RNA binding proteins, such as hnRNP L-like 
(hnRNP LL) and hnRNP E2, also associate with ESS1. Moreover, binding of these 
proteins also can be disrupted by the three point mutations within the ESS1 sequence 
(Rothrock et al., 2005; Topp et al., 2008).  
        To directly study the silencing activity of hnRNP L, Dr. Ganesh Shankarling in the 
Lynch lab set up the MS2-tethering system, an ESS1-independent splicing assay, to 
recapitulate hnRNP L-induced exon skipping. In the MS2-tethering system, the MS2-
exon 4 minigene is created by replacing the ESS1 element on CD45 exon 4 with an MS2-
hairpin sequence and hnRNP L is expressed as an MS2 fusion protein (Figure 3.6A). 
Expression of MS2-hnRNP L fusion protein specifically repressed the inclusion of the 
exon containing the MS2-hairpin sequence but not the exon with the mutated MS2-
hairpin (Figure 3.6B and C). Therefore, MS2-hnRNP L specifically represses the 
inclusion of MS2-exon 4 by binding to the MS2-hairpin sequence within the exon. 
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Figure 3.6 MS2-tethering system for studying hnRNP L-regulated alterantive 
splicing. (A) Schematic of MS2-tehtering system. MS2-hnRNP L fusion protein 
specifically associates with the MS2-hairpin-containing exon of the 3-exon pre-mRNA. 
(B) The expression levels of MS2-hnRNP L proteins in 293 cells transfected with the 
indicated amount of an MS2-hnRNP L expression construct. (C) Specific and robust 
repression of exon inclusion via the MS2-hnRNP L fusion protein. Quantification of RT-
PCR analysis of the splicing in 293 cells expressing different levels of MS2-hnRNP L. 
Additionally, the 293 cells are also transfected with either wildtype-MS2-hairpin-
containing minigene (MS2) or the minigene in which the MS2-hairpin sequence is 
mutated (MS2-mu) and thus does not bind MS2 fusion protein. 
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           To directly link the molecular interactions within the C-15 region to the silencing 
activity of MS2-hnRNP L, the C-15 region within the MS2-exon 4 is further mutated to 
determine whether hnRNP A1 and the U1 snRNA binding at the C-15 region is required 
for MS2-hnRNP L-mediated splicing repression in the MS2-tethering system. 
Importantly, the skipping of MS2-exon 4 is reduced upon introducing QC9 or A-to-C 
mutation into the C-15 region or upon knockdown of hnRNP A1 (Figure 3.7A and B). 
Therefore, MS2-hnRNP L induces the skipping of MS2-exon 4 by the same mechanism, 
as does hnRNP L bound to the ESS1 within CD45 exon 4. 
 
                  
Figure 3.7 The sequence integrity of the C-15 region and hnRNP A1 are required 
for MS2-hnRNP L-mediated splicing repression in the MS2-tethering system. (A) 
Top, RT-PCR and bottom, quantification of the skipping of exons containing wildtype or 
mutated C-15 region in an MS2-tethering system. (B) Top, RT-PCR and bottom, 
quantification of the skipping of wildtype exons regulated via MS2-hnRNP L upon 
knockdown of hnRNP A1 or L. 
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3.4 The linker region of hnRNP L recruits hnRNP A1 and is required for exon 
repression 
        The MS2-tethering system described in chapter 3.3 is a robust tool for dissecting the 
protein domains of MS2-hnRNP L that are involved in regulating alternative splicing. As 
described in the chapter 2.9, I showed that the crosslinking of hnRNP A1 to G-16 
nucleotide is dependent on the ESS1 element within CD45 exon 4. Moreover, addition of 
excess recombinant hnRNP L into the UV crosslinking assays promotes association of 
hnRNP A1 with G-16 (Figure 3.8A). This indicates that the domains of hnRNP L that are 
involved in recruiting hnRNP A1 to G-16 could be required for inducing exon skipping.  
         To determine the domains of hnRNP L that are involved in association with hnRNP 
A1, Dr. Ganesh Shankarling in the Lynch lab used epitope-tagged hnRNP L that is 
expressed in cells to precipitate hnRNP A1 from cell extract. Interesting, the ability of 
hnRNP L to co-precipitate hnRNP A1 depends on a proline-rich linker sequence within 
hnRNP L (Figure 3.8B and C). To further demonstrate that the interaction between 
hnRNP L and A1 is required for silencer activity of hnRNP L, different domain deletion 
was created within MS2-hnRNP L in the MS2-tethering system. Specifically, deletion of 
the proline-rich linker sequence disrupts MS2-hnRNP L-mediated repression of exon 
inclusion whereas deletion of other sequences that are not required for binding to hnRNP 
A1 has no effect on the repression activity of hnRNP L (Figure 3.8D). Therefore, it 
suggests that hnRNP L recruits hnRNP A1 to the C-15 region via its proline-rich linker 
domain to induce the skipping of exon 4. 
 
 64 
   
Figure 3.8 The linker domain of hnRNP L interacts and recruits hnRNP A1 to exon 
4 to achieve splicing repression. (A) UV crosslinking analysis as in Figure 2.10 in the 
presence of indicated amount of purified, recombinant GST-L. (B) Schematic of hnRNP 
L domains included in MS2 fusion proteins. FL contains the completed hnRNP L protein 
sequence fused downstream of the MS2 protein as used in Figure 3.6. ΔLink lacks the 
hnRNP L sequence between RRM2 and 3. ΔR34 lacks all RRM 3 and 4. (C) Co-
precipitation of hnRNP A1 with hnRNP L. Flag-MS2 control or Flag-MS2-hnRNP L 
containing various domain deletion shown in panel B was expressed in 293 cells 
followed by immunoprecipitation using anti-FLAG-antibody. The co-precipitated hnRNP 
L and hnRNP A1 proteins were analyzed with anti-hnRNP A1 or anti-FLAG antibodies. 
(D) RT-PCR (Topp et al.) and quantification (bottom) of the skipping of wildtype MS2-
exon 4 as in Figure 3.6, comparing the activity of the indicated MS2-hnRNP L deletion 
mutants relative to full-length. 
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3.5 Induction of extended U1 interaction may play a general role in regulating 
alternative splicing 
          An important question from these data is whether the hnRNP L and A1-induced 
extended pairing of U1 snRNA is unique to exon 4 or may play a more general role in 
splicing regulation. It has been shown that PSI regulates the splicing of P-element by 
directly interacting with U1 snRNP 70K protein and hrp48, a protein similar to the 
mammalian spicing factor hnRNP A1 (Labourier et al., 2001; Siebel et al., 1992; Siebel 
et al., 1994). The hnRNP A1-mediated induction of the extended U1 pairing with the 
substrate may be responsible for the splicing regulation of P-element. Moreover, recently, 
the group of Gene Yeo performed a genome-wide analysis of hnRNP A1 binding sites 
and hnRNP A1-regulated alternative splicing events by Clip-seq and micrrarrary-
detection of variable exons (Huelga et al., 2012). These studies revealed that hnRNP A1 
dominantly binds within the 3’ terminal 50 nucleotides of exons. Additionally, binding of 
hnRNP A1 to this region correlates with the its activity to induce the skipping of the exon 
(Figure 3.9). Such biased localization of hnRNP A1 suggests that fostering extended 
interactions of the 5’ splice site bound U1 snRNA with neighboring exonic sequences 
may be a widespread mode of hnRNP A1 action.  
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Figure 3.9 HnRNP A1 binds significantly at the 3’end of the exons it represses. RNA 
splicing maps showing the fraction of microarray-detected cassette exons with CLIP-seq 
reads located proximal to activated (positive y axis, blue), represses (negative y axis, 
red), and unaffected cassette exons (reflected on positive and negative y axis, transparent 
gray). Light blue shading sequences in the cassette exon (middle left, 0 to 50; middle 
right, -50 to 0). Black dots represent nucleotide positions where significantly more 
hnRNP-A1-repressed cassette exons showed binding. Adapted in part from (Huelga et al., 
2012).  
 
 
        To investigate the generality of the inducible U1 interaction in regulating alternative 
splicing, I further analyze the sequences within the 3’ end of the variable exons from 
Chemokine receptor 6 (CCR6) and Globin gene that are regulated by hnRNP A1 and L, 
respectively (Huelga et al., 2012; Rothrock et al., 2005). Surprisingly, both of the 
variable exons from these two genes contain the sequences that are potentially involved 
in pairing with the 3’ helix H region of U1, which could result in inducing the extended 
pairing interactions from the 5’ splice site bound U1 snRNP (Figure 3.10). Comparison 
of the sequences of other exons regulated by hnRNP L and A1 will be required for 
identifying more exons that are potentially regulated by inducting extended U1 
interactions. 
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Figure 3.10 Induction of the extended U1 interaction with substrate may be the 
mechanism for hnRNP L and A1 in inducing the skipping of other variable exons. 
Sequence analysis of the 3’ end of the variable exons in Chemokine receptor type 6 and 
Globin gene. The sequences within the exon that could be potentially associated with 
hnRNP A1 and 3’ helix H of the U1 snRNA are in orange and pink color, respectively.  
The sequences in bold text are in the exonic region. The sequences of the 5’ splice site 
are paired with the 5’end of the U1 snRNA (yellow box in U1).  
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          As the splicing of Globin exon 1 can be regulated by hnRNP L and the 3’ exon of 
Globin exon 1 also contains the UGCU motif that could potentially base-pair with the U1 
snRNA (Figure 3.11A; pink region of globin E1 5’ ss), I performed the psoralen 
crosslinking assays with the 5’ss RNA fragment from the Globin exon 1. Unfortunately, 
although there is an U1-dependent U+2 crosslink at the 5’ss, there are no crosslinks 
upstream of the Globin 5’ss that are dependent on the U1 snRNP in nuclear extract 
(Figure 3.11B). Supershift assays also revealed that the psoralen-crosslinked 5’ ss RNA 
fragment from Globin exon 1 lacks the supershifted band that contain the U1 snRNA 
crosslinked to the 3’ end of exon (Figure 3.11C). It is very likely that the sequences 
flanking the UGCU motif influence the psoralen-crosslinking efficiency at the 3’ end of  
Globin exon 1. However, it is still possible there are contacts between the U1 snRNA and 
the Globin exon which are required for hnRNP L-dependent splicing repression. 
Therefore, future work will be to determine whether the splicing of Globin exon 1 or 
CCR6 exon 6 is dependent on the integrity of the sequences within the 3’ end of these 
exons. 
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Figure 3.11 Interrogation of the U1-dependent crosslinks at the 3’ end of Globin 
exon 1 by psoralen crosslinking assays. (A) Comparison of the sequences around the 5’ 
ss between CD45 exon 4 and globin exon. (B) Primer extension analysis of psoralen-
crosslinked sites with primer R2 as in Figure 2.4. Here, the 5’ss RNA fragments of CD45 
exon 4 and globin exon 1 were used for the psoralen crosslinking assays. The 5’ ss RNA 
fragment of exon 4 and globin exon are spanning from -45 to +76 and from -47 to +74, 
respectively. (C) Supershift analysis of the psoralen-crosslinked 5’ ss RNA fragment as 
in Figure 2.5C. 
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3.6 Discussion 
         In chapter 2, hnRNP L and hnRNP A1 are shown to together induce the extraneous 
U1 interaction with the exonic region. In this chapter, the hnRNP L/A1-induced U1-exon 
interaction is further demonstrated in repressing the splicing of the downstream intron of 
CD45 exon 4, which results in enhancing the splicing of the intron between the upstream 
and downstream exon  (Figure 3.12).  
                  
Figure 3.12 Model for association of hnRNP A1 and the U1 snRNA with the 3’end of 
exon 4 in repressing the splicing of exon 4. Association of hnRNP A1 and the U1 
snRNA with the 3’ en of exon 4 is required for hnRNP L in inducing the skipping of exon 
4. Creating QC9 and A-to-C mutations at the C-15 region or mutating ESS1 disrupts 
hnRNP L-induced exon skipping. 
 
 
       To provide this model, the splicing of 2-exon and 3-exon pre-mRNA containing 
different mutant sequences at the C-15 region was analyzed in vitro and in cells (see 
chapter 3.2). Moreover, MS2-tethering system was established to demonstrate that the 
linker region of hnRNP L recruits hnRNP A1 to repress the inclusion of exon 4 (see 
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chapter 3.3 and 3.4).  Finally, sequence analysis of the 3’ end of the other two exons that 
are regulated by hnRNP L or A1 showed that the extraneous U1 pairing interactions 
could occur on these exons (see chapter 3.5). 
         All of the evidence described above comes from mutating the pre-mRNA substrate 
to block the U1 snRNA binding at the C-15 region. As a complementary approach, 
creating mutations into the U1 snRNA will be required to fully prove the model as 
described in Figure 3.12. To demonstrate pairing interactions within the 3’ portion of 
helix H in U1 is involved in splicing repression, the U1 snRNA carrying mutations at the 
3’ portion of helix H while keeping helical form of helix H will be expressed in cells. 
This type of informational suppression analysis is known as suppressor U1 experiments 
(Roca and Krainer, 2009; Zhuang and Weiner, 1986).  Besides creating mutations into the 
3’ portion of helix H, the compensatory mutations in the 5’ portion of helix H should also 
be made to keep helical form of helix H. The simplest way to mutate U1 snRNA is to flip 
the 5’ portion and 3’ portion of helix H in U1. Expression of the suppressor U1 snRNA in 
cells will compete with the endogenous U1 snRNA to bind to the 5’ ss. If expression of 
the suppressor U1 snRNA enhances the inclusion of wild type CD45 exon 4 but not the 
exon containing mutant sequence at the C-15 region, it will further support that the 3’ 
portion of helix H in U1 is required for repressing the inclusion of exon 4 by pairing with 
the C-15 region. 
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Chapter 4 
HnRNP L and A1-induced extended U1 interaction blocks the catalytic complex 
formation by repressing the U1/U6 exchange at the 5’splice site 
  
          In the chapter 2 and 3, hnRNP L is shown to repress splicing by inducing an 
extended U1 interaction at the 3’ end of CD45 exon 4. Along the spliceosome assembly 
pathway, the RNA-RNA and RNA-protein interactions are extensively rearranged to 
allow splicing to occur. It is unknown how hnRNP L-induced extended U1 interaction 
blocks the spliceosome assembly to repress splicing. Therefore, as described in this 
chapter, I next set out to identify the spliceosome complexes, components or interactions 
that are altered by the hnRNP L-induced extended U1 interaction. These aberrant 
spliceosome interactions are further investigated to understand how they are regulated by 
hnRNP L to block the formation of the catalytically active spliceosome. 
 
4.1 Introduction 
4.1.1 Protein components of the spliceosome A, B and C complex 
        The human spliceosomal complexes contain ~45 distinct snRNP associated proteins 
and ~170 spliceosome associated factor (Jurica and Moore, 2003). During the splicing 
processes, snRNPs enter and leave the spliceosomes from one stage to the next (Figure 
1.3). Thus, the number of the total spliceosomal proteins varies among different pre-
spliceosomal intermediates. In general, each of the spliceosomal A, B and C complexes 
contains ~ 125 proteins (or less in the case of the A complex) (Wahl et al., 2009). Table 
4.1 lists some of these proteins that have the well-known functions.  
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Table 4.1 Protein components of the spliceosome A, B and C complex. The total 
number of protein components (in parenthesis) in each of the complexes and functions of 
some of these proteins are listed in the table. 
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       The spliceosomal A complex mainly consists of U1 and U2 snRNPs. During the 
progression from the A to B complex, ~35 U6/U4.U5 tri-snRNP proteins and ~25 non-
snRNP proteins are recruited (see Table 4.1). The major part of these non-snRNP 
proteins is the nineteen complex (NTC). The human Prp19 complex is comprised of 7 
distinct subunits with four copies of Prp19 protein (Grote et al., 2010). This complex is 
thus similar to the size of the snRNPs, but unlike the snRNPs, the NTC contains no 
RNAs.  
        The transition from the B to Bact complex involves the release of both of RNA and 
protein components of U1 and U4 snRNP (Figure 4.1). Although U6 snRNA is not 
released, most of its protein components also fall off before the formation of the Bact 
complex (Figure 4.1; U6 Lsm2-8). Moreover, although NTC interacts with the 
spliceosome at the stage of the B complex formation, its association is stabilized during 
the progression to the Bact complex (Behzadnia et al., 2007; Deckert et al., 2006; 
Makarova et al., 2004). It is possible that the NTC forms new interactions with U2, U5 or 
U6 snRNA such that its association in the Bact complex is stabilized. Association of the 
NTC with the spliceosome also promotes interaction of U6 snRNA with the splice sties 
of pre-mRNA in creating the active splice sites of the spliceosome (Chan and Cheng, 
2005). Among the protein components of the tri-snRNP, only U5 snRNP proteins remain 
associated with the spliceosome during the transition from the B to Bact complex (Table 
4.1; U5).  
        During the transition from the Bact to C complex, ~30 non-snRNP proteins are 
recruited (Table 4.1; C complex factors). Among these proteins, the RNA-dependent 
ATPases/helicases, Prp2, is shown to promote the catalytic step I to generate the 5’ exon 
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and the lariat intermediates in the C complex. Besides the splicing intermediates are 
generated, SF3b155 is dephosphorylated whereas CDC5L is phosphorylated during the 
progression from the Bact to C complex (Figure 4.1; compare Bact with C complex ). 
         
Figure 4.1 Compositional dynamics during the catalytic activation of the 
spliceosome. The components that are released or changed during the transition from the 
B to Bact complex or from the Bact to the C complex. The B complex contains all five 
snRNPs and NTC. To establish the catalytic site of spliceosome, The RNA and protein 
components of U1, U4 snRNP and the protein components of U6 snRNP dissociate while 
more NTC components are integrated at the time of activation. The yellow stars indicate 
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the protein components that are specifically phosphorylated in the Bact versus the C 
complex. Protein components of the B and C complex are listed in Table 4.1. 
4.1.2. Structural rearrangements during catalytic activation of the spliceosome 
        Along the spliceosome assembly pathways, there is an enormously intricate network 
of RNA-RNA interactions. As mentioned in chapter 2.2, the 5’ end of the U1 snRNA 
base-pairs with the 5’ splice site. Additionally, a stretch of GUAGUA sequence within 
the U2 snRNA is engaged in the pairing interaction with the BPS (Figure 4.2; cyan box 
of U2). The U5.U4/U6 tri-snRNP is recruited by U1 and U2 snRNP to form the B 
complex, in which the base-paring interactions between snRNAs and pre-mRNA are 
extensively rearranged to generate the C complex (Figure 4.2) (Staley and Guthrie, 1998; 
Wahl et al., 2009). One of the rearrangement events involves the disrupting the binding 
between the U1 snRNA and the 5’ ss to allow the highly conserved CAGAG motif of U6 
to base-pair with the 5’ end of the intron. Concomitant with, prior or posterior to this, U4 
snRNP is released to allow the formation of new U2/U6 base-pairing interactions, which 
is though to comprise the heart of the catalytic center of the spliceosome (Figure 4.2) 
(Madhani and Guthrie, 1992; Villa et al., 2002).  
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Figure 4.2 Dynamics of the network of RNA-RNA interactions during the catalytic 
activation of the spliceosome. Schematic of regions of U2 and U6 snRNA that undergo 
major rearrangements during the transition from the B to C complex. The GUAGUA 
sequence of U2 snRNA pairs with the BPS (cyan box of U2). The destabilization of U1 
allows the CAGAG motif of the U6 snRNA base pairs to the 5’ splice site (blue box of 
U6). The releasing of U4 allows the region next to CAGAG motif in U6 engages in the 
interaction with U2 (yellow box). Although here it shows that the release of U1 and U4 is 
two separated events, it is unknown which one occurs first or whether they occur 
concurrently. 
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          In the B complex, which does not yet have an active center, U4 and U6 snRNA are 
held firmly by base-pairing interactions while the U5 snRNA associates with U4 snRNA 
through RNA-protein interactions (Figure 4.3A). The U4 and U6 base-pairing 
interactions inactivate the catalytically important regions of U6 to prevent from cleaving 
pre-mRNA prematurely. During the catalytic activation of the spliceosome, U4/U6 base-
pairing interactions are taken apart, which frees U6 snRNA and allows the formation a 
catalytically important U6 internal stem loop (ISL) (Figure 4.3A; red box of U6). The U6 
snRNA that is not paired with U4 engages in the new basepairing interactions with the 
5’ss and the U2 snRNA. Interestingly, the U2/U6 basepairing interactions involve the 
region upstream of CAGAG motif of U6 and the region proximal to the GUAGUA 
sequence of U2 (Figure 4.3B), which allows the juxtaposition of two splice sites. 
Additionally, the stem loop region of U5 snRNA contacts the nucleotides of the 5’ and 
3’exon to bring the two exons into proximity (Figure 4.3B; U5). The network of RNA-
RNA interactions also brings U5 snRNP proteins close to the splice sites to create the 
catalytic center. A wealth of evidence shows that the U5 snRNP protein, prp8, is located 
at the heart of the spliceosome and the RNase H domain of Prp8 is thought to promote 
two catalytic steps (Query and Konarska, 2013). Thus, the network of RNA-RNA and 
RNA-protein interactions creates the catalytic active site of the spliceosome.  
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Figure 4.3 Remodeling of the U5.U6/U4 tri-snRNP. (A) Disruption of U4/U6 base-
pairing interactions in the tri-snRNP. After releasing from U4 snRNA, the U6 internal 
stem loop (ISL) forms a hairpin and the regions upstream ISL engages in new pairing 
interactions, as in panel B. (B) Schematic of critical base-pairing interactions in the 
catalytic spliceosome. For U5 and U2 snRNA, only the stem loop I of U5 and the internal 
region of U2 are shown. For U6 snRNA, the whole structure is depicted. The U6 ISL 
stabilizes the RNA network in the catalytic spliceosome.  
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4.2 The transition from the B to Bact/C complex is blocked on the repressed 
substrate 
        As mentioned in chapter 1.6, hnRNP L was previously reported to repress the 
progression from the spliceosomal A to B complex. To more rigorously characterize the 
assembled spliceosome complexes, I set to purify the complexes assembled on the 
repressed- and derepressed-substrate. To perform the affinity-selection of the assembled 
spliceosome, I engineered the MS2-hairpin sequence into the 3’end of the pre-mRNA 
(Figure 4.4) (Jurica et al., 2002; Zhou et al., 2002).  The MS-hairpin sequence can be 
tightly bound by MS2MBP protein without interfering splicing efficiency and 
spliceosome assembly. The MS2MBP-tagged spliceosome complexes in the spliceosome 
assembly reactions were immobilized onto the amylose beads. After rigorously washing 
away the non-specific protein and RNA components from the immobilized complexes, 
maltose solution was used to elute the complexes from the amylose resin. 
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Figure 4.4 MS2MBP affinity purification strategy used to isolate the complexes from 
the splicesome assembly reactions. About 2 pmol RNA substrates pre-bound by 
MS2MBP were incubated with 1.5 mg JSL1 nuclear extract followed by amylose-resin 
purification. The volume of the purified spliceosome is ~200 µl and the purification 
efficiency is ~10% so that the concentration of the purified spliceosome is ~ 1 nM. 
 
 
         To identify the snRNP components in the purified spliceosome, the RNA 
components of the purified complexes were isolated and analyzed by silver-staining. The 
presence of the snRNAs is the indicative of the presence of the snRNPs. It showed that 
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the H/E complexes purified from the ATP-depleted nuclear extract have no tri-snRNP 
and much lower levels of U2 snRNP (Figure 4.5A and B; -ATP). This is consistent with 
the fact that the association of these components requires ATP. This also suggests that the 
purification conditions are stringent enough to wash away the ATP-dependent 
components from the complexes assembled in the ATP-depleted nuclear extract. 
Strikingly, the purified repressed and derepressed complexes assembled in the presence 
of ATP contain similar levels of the tri-snRNP (Figure 4.5A; +ATP). Thus, the middle 
band resolved from the repressed complexes may be the mixture of the A and the tri-
snRNP-containing B complex (Figure 4.5D; A/B).  
        As mentioned in chapter 1.6, the tri-snRNP was not thought to associate with the 
repressed substrate because the B complex is not assembled on the repressed substrate in 
a native gel (Figure 4.5B). The label of the complexes in a native gel is based on the fact 
that the formation of the top band but not the middle band is reduced when the U6 snRNP 
is depleted from the nuclear extract (Figure 4.5B; +ATP, -U6). To more accurate 
determine the snRNP components, I purified complexes assembled in nuclear extract 
depleted of U6 activity by the cleavage of U6 snRNA. This showed that the purified 
complexes assembled in the U6-depleted nuclear extract contain the tri-snRNP in which 
the U6 snRNA is cleaved (Figure 4.5C; +ATP, -U6). This indicates that cleavage of U6 
snRNA does not inhibit recruitment of tri-snRNP but may repress the subsequent tri-
snRNP rearrangements required for the formation of the Bact or C complex, which 
migrates shower than the B complex as shown by other groups (Bessonov et al., 2010). 
Thus, the top band could be the mixture of Bact and C complex, which is supposed to be 
reduced when the U6 snRNA is cleaved (Figure 4.5D). Based on this conclusion, I re-
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label the complexes in a native gel so that the new label of the middle band is A/B 
whereas the top band is renamed as Bact/C (Compare Figure 4.5D with B; labels in red 
color).  
          
 
Figure 4.5 The tri-snRNP is associated with both of the repressed and derepressed 
complexes even when the B complex is not resolved in a native gel. (A) Silver-staining 
of the RNA components extracted from the purified complexes assembled in the absence 
(-ATP) or in the presence of ATP (Total). (B) Spliceosome assembly assays, as in Figure 
1.10D. (C) Silver-staining of the RNA components extracted from the purified complexes 
assembled in the absence (-ATP), in the presence of ATP (Total) or in the U6-depleted 
nuclear extract (-U6). (D) Spliceosome assembly assays, as in panel B, with new labels. 
 
 84 
          In general, spliceosome assembly reactions are treated with heparin, a highly 
sulfated glycosaminoglycan, to allow the resolution of the assembled complexes in a 
native gel (Figure 4.6A). Without adding heparin into the spliceosome assembly 
reactions, it showed that most of the reactions are stuck in the well and no obvious 
assembled complexes are resolved in a gel  (Figure 4.6B).  
 
              
 
Figure 4.6 Heparin is required for resolution of complexes in a native gel in the 
splicesome assembly assays. (A) Schematic of the addition of heparin into spliceoosme 
assembly assays before native gel eletrophresis. (B) Native gel electrophoresis of the 
gradient fractions. When heparin was not added into the spliceosome assembly reactions, 
no obvious complexes are resolved in a native gel. 
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         After gradient fractionation of the spliceosome assembly reactions, heparin is also 
added into fractions before native gel electrophoresis (Figure 4.7A). Unexpectedly, in the 
absence of heparin, the complexes in glycerol-gradient fractions can be resolved in a 
native gel (Figure 4.7; no heparin). It is likely that during the glycerol-gradient 
centrifugation, the non-specific proteins or RNAs are removed from the assembled 
complexes to allow their migration in a native gel. Strikingly, in the conditions without 
heparin, both of the A and B complex are resolved from the middle fractions containing 
the repressed substrate. Moreover, the Bact/C complex is resolved from the later fractions 
containing the derepressed substrate (Figure 4.7B; no heparin). It is possible that heparin 
reorganizes the complexes in the middle fractions so that the A and B complex comigrate 
into a single band in the conditions with heparin. Additionally, the Bact/C complex is 
reorganized by heparin as well so that it migrates faster in the conditions with heparin 
than without heparin (Figure 4.7B; compare heparin with no heparin). Thus, the native-
gel analysis of the spliceosome in gradient fractions further supports that binding of 
hnRNP L to ESS1 on the repressed substrate does not sterically inhibit the tri-snRNP 
association, but instead, it interferes the subsequent transition into the Bact/C complex.  
        Other groups also observed that the complex, which is called as the A complex in a 
native gel in the presence of heparin, contain the tri-snRNP after purification (Roybal and 
Jurica, 2010; Schneider et al., 2010a; Schneider et al., 2010b). Therefore, MS2MBP-
affinity purification of the spliceosome provides more accurate analysis of the snRNP 
composition of the complexes assembled on the pre-mRNA substrates. 
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Figure 4.7 Analysis of the ESS1-repressed complexes in gradient fractions 
demonstrated that the B complex is assembled but its transition to the Bact/C 
complex is blocked. (A) Schematic of addition of heparin into the gradient fractions 
before native gel electrophoresis. (B) Native gel electrophoresis of the gradient fractions 
in the absence and in the presence of heparin. Here, fractions no. 7-11 are E fractions; 
no.12-16 are M fractions; and no. 17-21 are L fractions. Identifies of the complexes were 
primarily based on their migration in the native gel. Base on the results in the presence of 
heparin, there are new labels for the spliceosome complexes in the absence of heparin. 
Middle band is labeled as comigration of the A and B complexes (A/B). Top band is 
labeled as the mixture of the Bact and C complex (Bact/C). 
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4.3 Derepressed complexes display higher levels of the hallmarks of the Bact/C 
complex  
        As described in chapter 1.3 and 4.1, the formation of the catalytic complex results in 
the release of U1 and U4 snRNP and generation of splicing intermediates and products. 
To investigate whether these components are different in repressed versus depressed 
complexes, I set to analyze the complexes purified from the gradient fractions. To have a 
negative control to show that the purification conditions are stringent enough to wash 
away the non-specific protein and RNA components, the spliceosome are assembled in 
the ATP-depleted nuclear extract to accumulated E complex followed by glycerol 
gradient centrifugation (Figure 4.8).  
    
Figure 4.8 Gradient fractionation of the complexes assembled in nuclear extract 
depleted of ATP. Native gel electrophoresis of gradient fractions as in Figure 4.4 in the 
absence of heparin. In comparison to Figure 4.4, the complexes are assembled in the 
ATP-depleted nuclear extract before gradient centrifugation. 
  
 
         To further analyze the RNA and protein components that are associated with the 
repressed and derepressed complexes, MS2MBP-tagged spliceosome complexes 
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assembled in the absence ATP (Figure 4.8) or in the presence of ATP (Figure 4.7) were 
fractionated by glycerol gradient centrifugation followed by the amylose column 
purification.  
         The complexes purified from ATP-depleted nuclear extract are not associated with 
the tri-snRNP, which demonstrates that the washing conditions are stringent enough to 
eliminate the nonspecific association of snRNPs (Figure 4.9A; -ATP). Additionally, both 
of the repressed and derepressed complexes purified from M fractions contain similar 
levels of tri-snRNP, which is consistent with the fact that the B complex is assembled in 
M fractions (Figure 4.9A; M fractions). Surprisingly, the repressed and derepressed 
complexes purified from the L fractions contain similar levels of all five snRNAs 
although I expected to see the reduced levels of U1 and U4 snRNA in the purified Bact/C 
complex assembled on the derepressed substrate (Figure 4.9A; L fractions). It is likely 
that on the derepressed substrate, the released U1 and U4 snRNP still weakly associate 
with the C complex so that the purification strategy or silver-staining is not sensitive 
enough to detect the decreased levels of U1 and U4 in the C complex. Western blot 
analysis of the purified complexes revealed that the levels of NTC protein components, 
including Prp19, CDC5L, PLRG1 and SPF27, are higher in the derepressed than 
repressed complexes purified from L fractions (Figure 4.9B). As mentioned in chapter 
4.1, during the transition into the Bact complex, the levels of NTC association is 
stabilized. Phosphorimaging analysis of the purified repressed and derepressed 
complexes showed that that the amount of lariat intermediates is higher in the 
derepressed than repressed complexes purified from the L fractions (Figure 4.9C). This 
suggests that the Bact complex is progressed into the C complex on the derepressed 
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substrate. Therefore, in comparison to the repressed substrate, the derepressed substrate 
display the higher levels of hallmarks of the Bact/C complex, including the enhanced NTC 
association and increased levels of splicing intermediates. 
 
                                
Figure 4.9 The levels of splicing intermediates and NTC association are higher in the 
purified derepressed than repressed complex in L fractions. (A) Silver-staining of the 
RNA components extracted from the purified complexes which were assembled in the 
ATP-depleted NE and then sediment into E fractions (Figure 4.8; -ATP) or assembled in 
the presence of ATP and then sediment into E, M or L gradient fractions (Figure 4.7B; 
+ATP). (B) Top, western blots and bottom, quantification of proteins in the purified 
complexes as in panel B. (C) Phosphorimaging analysis of the pre-mRNA, spliced 
products and splicing intermediates, including the lariat intermediate and 5’ exon in the 
purified complexes, as in panel A.  
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4.4 Association of hnRNP A1 and the U1 snRNA with the 3’ end of exon 4 is 
required for ESS1-dependent repression of the Bact/C complex formation 
        To confirm the requirement of the U1 snRNA and hnRNP A1 binding for the 
repression of the Bact/C complex formation, the spliceosome assembly assays were 
reconstituted with the substrates containing mutations at the C-15 region. Indeed, these 
mutations enhance the formation of the top band, which is supposed to be the Bact/C 
complex (Figure 4.10A).  
         To further support that the recruitment of the U1 snRNA and hnRNP A1 at the 
3’end of exon 4 is required for ESS1-mediated repression of the Bact/C complex 
formation, complexes assembled on the substrates containing mutations at the C-15 
region were further purified. It revealed that the levels of Prp19 and CDC5L are 
increased when association of hnRNP A1 and the U1 snRNA is disrupted by mutations at 
the C-15 region (Figure 4.10B) or in the presence of anti-E4 oligo (Figure 4.10C). As 
enhanced NTC association is a hallmark of the Bact/C complex formation, I conclude that 
ESS1/hnRNP L represses the Bact/C complex formation by recruiting hnRNP A1 and the 
U1 snRNA to the 3’ end of CD45 exon 4. 
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Figure 4.10 The sequence integrity of the C-15 region is required for ESS1-
dependent repression of the Bact/C complex formation and NTC recruitment. (A) 
Spliceosome assembly assays, as in Figure 4.6B, with the indicated substrates. (B) Top, 
western blots and bottom, quantification of proteins in the purified complexes which 
were assembled on the indicated substrates in the presence of ATP and then sediment into 
L fractions. (C) Western blots of proteins in the purified complexes which were 
assembled in the presence or absence of anti-E4 oligo and then sediment into L fractions. 
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4.5 The transition from U1 to U6 binding at 5’ splice site is repressed by the hnRNP 
L-induced extended U1 interaction  
         As described in chapter 4.1.2, several paring interactions are rearranged during the 
transition into the C complex. Since the extended U1 interaction could function in hyper-
stabilizing binding of U1 snRNP to the 5’ss, the most likely rearrangement event that is 
altered by hnRNP L is the transition from U1 to U6 snRNP binding at the 5’ ss (Figure 
3.1A). 
        To access the state of U6 snRNP binding at the 5’ ss, I performed the oligo-induced 
RNase H cleavage to interrogate the accessibility of the ACAGAG box of U6. In this 
assay, splicing complexes purified by MS2MBP-affinity selection were treated with 
varying concentrations of an oligo complementary to the ACAGAG box of U6 to induce 
RNase H cleavage (Figure 4.11A). The ACAGAG box of the U6 snRNA is unpaired 
when U6 is paired to U4 as part of the tri-snRNP, and thus should be highly accessible to 
RNase H cleavage (Figure 4.2; B complex). By contrast, when the U6 snRNA replaces 
U1 at the 5’ splice site, the CAGAG box region of U6 become paired with the 5’ss, 
which should protect it from RNase H cleavage (Figure 4.2; C complex). If ESS1 blocks 
the replacement of U1 by U6, there would be less association of U6 snRNA with the 5’ 
ss. Indeed, I observed less U6 protection in the repressed versus derepressed complexes 
at all concentrations of oligo tested (Figure 4.11B). Importantly, the extended U1 
interaction with the 3’end of exon 4 is required for reducing U6 accessibility for 
cleavage, as the QC9 mutation increases the relative protection of U6, indicative of 
increased association of U6 with the 5’ splices site. 
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Figure 4.11 HnRNP L-induced extended U1 interaction represses association of U6 
snRNP with the 5’ splice site. (A) Schematic of RNase H-protection assays for 
accessing the pairing interactions in the CAGAG motif of U6 with the 5’ss. (B) Top, 
primer extension analysis; bottom, quantification of the cleaved and protected U6 
snRNA. 
 
 
 
          If hnRNP L blocks association of U6 with the 5’ss to repress splicing, enhancing 
interaction of U6 snRNA with the 5’ splice site would disrupt hnRNP L-mediated 
splicing repression (Figure 4.12A). Thus, I mutated the sequence downstream of the 5’ ss 
to artificially extend the pairing interactions between U6 snRNA and the 5’ ss (Figure 
4.12B). Indeed, I observed increased splicing of the repressed substrate when the U6-5’ss 
pairing interaction is extended whereas the splicing of the derepressed substrate has only 
minor increase with this enhanced U6 binding (Figure 4.12C). Moreover, the control 
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mutations have no effect on exon 4 splicing. Since enhancing association of U6 snRNP 
with the 5’ ss overcome the effect of the hnRNP L-induced extended U1 interaction, I 
conclude that hnRNP L represses splicing through inhibiting the U1/U6 switch at the 
5’ss. 
 
          
Figure 4.12 HnRNP L represses the exchange of U1 by U6 at the 5’ splice site. (A) 
Schematic of the potential effect of enhancing the interactions of U6 with the 5’ splice 
site. (B) Schematic of sequences of U6 enhanced (U6) and control mutations made in the 
region downstream of the 5’ splice site. (C) In viro splicing assays with the substrates 
indicated in panel B. 
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4.6 Binding of Prp8 may be interfered by hnRNP A1 and the U1 snRNA binding at 
the 3’ end of exon 4 
         As mentioned from the chapter 4.1.2, concomitant with, prior or posterior to the 
U1/U6 switch, the contacts between U5 snRNP and splice sites are formed. It has been 
shown that the U5 snRNP component, Prp8, can be crosslinked to the 5’ ss (Grainger and 
Beggs, 2005).  To investigate whether the extended U1 interactions interferes the contacts 
of U5 snRNP with splice sites, the G residue which is 15 nucleotide downstream of the 5’ 
ss (G+15) on the repressed substrate is radio-labeled (Figure 4.13A). UV crosslinking 
assays showed that there is a ~250 KDa protein that is crosslinked to the G+15 when 
hnRNP A1 and the U1 snRNA binding are blocked by the anti-3’E4 oligo (Figure 4.13B). 
This suggests that binding of hnRNP A1 and the U1 snRNP at the 3’end of exon 4 also 
disrupts the association of Prp8 with the 5’ ss. Since repressing U1/U6 switch may 
interfere the subsequent interaction of Prp8 with the 5’ss, the reduced level of Prp8 
crosslinked to the 5’ss may not be an direct effect caused by the A1 and U1 binding at the 
3’ end of exon 4. However, the timing of these structural rearrangement events is 
debatable. Therefore, it is possible that hnRNP A1 binding at the 3’end of exon 4 
sterically blocks association of Prp8 with the 5’ ss, thereby repressing the U1/U6 switch. 
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Figure 4.13 Blocking association of hnRNP A1 and the U1 snRNA with the 3’ end of 
exon 4 enhances crosslinking of a ~250KDa protein to the G+15 nucleotide. (A) 
Schematic of the site-specific labeled RNA containing a radiolabeled phosphate at G+15. 
(B) Analysis of proteins crosslinked to G+15 nucleotide of the repressed substrate in the 
absence (-) or presence (+) of anti-3’E4 oligo in a SDS-PAGE. 
 
 
 
 
4.7 Discussion 
           Spliceosome assembly has been described to be the stepwise assembly of snRNPs 
on the pre-mRNA. The studies in this chapter showed that hnRNP L represses exon 4 
splicing by trapping the 5’ss-bound U1 snRNP in a stabilized conformation that inhibits 
the subsequent replacement of U1 by U6 at the 5’ss, thereby blocking the structural 
rearrangements required for the catalytic complex formation (Figure 4.14). 
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Figure 4.14 Model for hnRNP L function in repressing the U1/U6 switch at the 5’ 
splice site to repress the formation of the Bact/C complex. The hnRNP L-induced 
extended U1 interaction within the B complex represses association of U6 with the 5’ss, 
which represses structural rearrangements required for the Bact/C complex formation. As 
a result, the splicing of the downstream is repressed. By contrast, the canonical binding of 
U1 at the 5’ ss in the derepressed B complex allows the progression to the Bact/C complex 
and the subsequent splicing catalysis. 
 
 
         It has been shown that the transfer of the 5’ ss from the 5’ end of U1 snRNA to the 
ACAGAG motif of U6 snRNA is facilitated by the RNA helicase, Prp28 (Staley and 
Guthrie, 1999). Moreover, it has been demonstrated that artificially lengthening the U1-
5’splice site duplex represses the replacement of U1 by U6 at the 5’ ss (Staley and 
Guthrie, 1999). In this study, I showed that the extended interactions between U1 3’ helix 
H and the 3’ end of the exon could function similarly as the lengthened U1-5’ ss duplex 
in stabilizing U1 snRNP binding to repress the Prp28-mediated U1/U6 switch at the 5’ss. 
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Besides lengthening basepairing interactions, U1C has been reported in stabilizing the 
U1-5’ss duplex. Moreover, mutation within U1C that disrupts its stabilization activity 
allows yeast to bypass the function of Prp28 (Chen et al., 2001). This further support that 
the stability of U1 snRNP binding at the 5’ss could influence the ability of Prp28 to 
mediate the subsequence rearrangement of spliceosome interactions.  
          To repress the catalytic activation of the spliceosome, besides the U1/U6 switch, 
the U5 snRNP component, Prp8, is possibly repressed by hnRNP A1 and the U1 snRNA 
in the hnRNP L-repressed complex (see chapter 4.5 and 4.6). During the catalytic 
activation, U4 is released from U6 to allow the formation of the U6/U2 duplex, which is 
mediated by the RNA helicase, Brr2 (Staley and Guthrie, 1998). Moreover, Prp8 has 
been shown to mediate the helicase activity of Brr2 (Mozaffari-Jovin et al., 2012). Thus, 
it is possible that the reduced binding of Prp8 on the repressed complex could interfere 
the activity of Brr2 for unwinding U4/U6 duplex. If Prp28, Prp8 or Brr2 all are located 
nearby the 5’ splice site on the repressed substrate, it is also possible that the hnRNP L 
and A1 in the C-15 region directly influence the activities of these proteins. It would 
provide significant insight if I can detect the interactions between hnRNP L or A1 with 
spliceosome components bound at the 5’ss, including U1 snRNP, Prp28, Prp8 and Brr2. 
These molecular interactions could provide a light about other targets of hnRNP L or A1. 
Therefore, although I showed that the U1/U6 switch could be repressed directly by the 
extended U1 interactions at the 3’ end of exon 4, other spliceosome components that 
interact with the 5’ss could be sterically blocked by hnRNP L or A1 to repress other 
structural rearrangement events during the catalytic activation. 
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Chapter 5 
Conclusions and future directions  
 
          Although the 5’ splice site on the pre-mRNA is defined by the sequence in the -3 to 
+6 region of the 5’ ss, a multitude of factors have been demonstrated to contribute to 5’ 
selection (Roca et al., 2013). In chapter 2, 3 and 4, I demonstrated a novel mechanism 
showing that ESS1/hnRNP L-induced binding of hnRNP A1 upstream of the 5’ splice 
site causes an extended form of U1 snRNP, which represses the switch of U1/U6 at the 5’ 
ss. In addition to the ESS1 element within CD45 exon 4, the exon-definition interactions 
formed across exon 4 also have been shown to mediate splicing repression (House and 
Lynch, 2006). Importantly, fully understanding the mechanisms of splicing choices has 
implications for predicting splicing patterns and genetic diseases. Based on the 
conclusion from chapter 2, 3, and 4, in this chapter, I discuss the future directions for 
understanding how exon-definition interactions, splicing regulators and spliceosome 
components could be combined to regulate 5’ ss choices. 
 
5.1 Forming exon-definition interactions is involved in ESS1-mediated splicing 
repression 
       As mentioned in chapter 1.3, in vertebrate cells, the average length of exons is about 
10-fold longer than the intron, so that the exon-definition interactions are believed to 
occur before intron-definition interactions. The exon-definition interactions could occur 
in any spliceosome intermediate complexes and the transitions from exon- to intron-
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defined complex could function as regulation points for alternative splicing (House and 
Lynch, 2008).  
        Within the hnRNP L-repressed B complex, U2 snRNP that associates with the 
upstream intron could form cross-exon interactions with spliceosome components in the 
downstream intron (Figure 5.1A). To disrupt the exon-definition interactions that are 
mediated by binding of U2 snRNP at the upstream intron, we removed the upstream 
intron to generate the R Δ3’ss or D Δ3’ss substrate (Figure 5.1B) (House and Lynch, 
2006). The in vitro splicing assays showed that after removing the upstream intron, the 
splicing of the downstream intron is increased and is no longer regulated by the ESS1 
element (Figure 5.1C). Moreover, spliceosome assembly assays demonstrated that the 
progression from the B to Bact/C complex is enhanced on the Δ3’ss substrates (Figure 
5.1D). Thus, the exon-definition interactions within the B complex assembled are 
required for ESS1-mediated repression of the Bact/C complex formation. 
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Figure 5.1 Exon-definition interactions are required for ESS1 to repress the splicing 
of CD45 exon 4 in vitro. (A) Comparison of exon-definition interactions between the 
substrates with upstream intron (left) and without the upstream intron (right). (B) 
Schematic of splicing substrates. In contrast to R and D substrate, RΔ3’ss and RΔ3’ss 
substrate have no upstream intorn. (C) RT-PCR analysis of the RNA in the in vitro 
splicing reactions containing the substrates as in panel B. (D) Native acrylamide gel 
electrophoresis of the spliceosome assembly reactions reconstituted with the indicated 
substrates.  
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         It has been shown that binding of hnRNP A1 or the U1 snRNA at the C-15 region is 
also required for repressing the transition from the B to Bact/C complex (Figure 4.8). 
Thus, it is likely that exon-definition interactions are required for the ESS1-dependent 
recruitment of hnRNP A1 and the U1 snRNA into the C-15 region. It is also possible that 
the exon-definition interactions interferes other structural rearrangement events during 
the progression into the Bact/C complex. As the structures of U2 and tri-snRNP are 
flexible and they undergo the extensive structural changes during the catalytic activation, 
it is likely that the U2 snRNP bound in the intron upstream of CD45 exon 4 is extended 
to interact with the tri-snRNP in the intron downstream of exon 4 to interfere their 
rearrangement during the progression into the Bact/C complex. Future work will be to 
determine how the exon-definition interactions in the B complex interferes the U1 snRNP 
binding and tri-snRNP structural changes that are required for the Bact/C complex 
formation (Figure 5.2; question marks).  
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Figure 5.2 Exon-definition interactions within the repressed B complex may 
interfere U1 snRNP binding or rearrangements of the tri-snRNP. Exon-definition 
interactions formed across CD45 exon 4 are required for hnRNP L-repressed spliceosome 
assembly. It is unknown how exon-definition interactions function in hnRNP L-mediated 
repression of the Bact/C complex formation. It is possible that spliceosome components or 
interactions at the 5’ splice site on the downstream intron are repressed by the U2 snRNP 
bound on the upstream intron. 
 
 
 
 
 
 
5.2 Splicing regulators bound around the 5’ ss interfere U1 snRNP binding or 
induce conformational change of U1 snRNP to regulate splicing 
         As mentioned in chapter 2, one of the novelties of my data is identification of 
extraneous spliceosome interaction within the exon that is involved in repressing use of 
the nearby 5’ss. Specifically, I showed that helix H in U1 snRNA unwinds to allow the 3’ 
portion of helix H to basepair with the 3’ end of CD45 exon 4. Additionally, this novel 
extraneous spliceosome interaction is extended from the 5’ splice site-bound U1 snRNP 
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since reducing the recruitment of U1 snRNP to the 5’ ss by cleaving the 5’ end of the U1 
snRNA abolishes the novel pairing interaction at C-15. Other studies also showed that the 
conformation of U1 snRNP binding at the 5’ ss is altered such that the regions of the 5’ ss 
that are protected against nucleases are changed upon repressing use of the 5’ ss by 
splicing regulators (Sharma et al., 2011; Yu et al., 2008). Although the molecular basis 
and roles for such a conformational change are unknown, my findings suggest that 
unwinding helix H in U1 snRNA to make contacts with substrate is a possible way to 
change the conformation of U1 binding at the 5’ ss.  
        The other novelty of my data is the demonstration that association of hnRNP A1 
with a low-affinity binding site upstream of the 5’ ss induces the extended U1 interaction. 
HnRNP A1 typically acts by competition with SR proteins and U1 snRNPs for binding to 
pre-mRNA in the presence of the high-affinity binding site (Eperon et al., 2000). 
Specifically, high affinity sites nucleate cooperative binding of hnRNP A1 that can 
displace other factors, such as the U1 snRNP, as it spreads along the RNA (Okunola and 
Krainer, 2009). Therefore, the low binding affinity of hnRNP A1 at the 3’ end of exon 4 
may allow hnRNP A1 to induce the extended conformation of U1 snRNP but limit its 
nucleation ability to spread along the 5’ss for displacing U1 snRNP from the 5’ ss.  
         By contrast, TIA-1 has been shown to associate with the sequence downstream of 
the 5’ ss to enhance U1 snRNP binding (Del Gatto-Konczak et al., 2000). Therefore, 
although the 5’ ss is defined by the consensus sequence ranging from -3 to +6 relative to 
the 5’ ss, the sequences flanking the -3 to +6 region of the 5’ss should also be considered 
when determining the usage or strength of the 5’ ss. 
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5.3 Besides U1 snRNP, other spliceosome components that are associated with the 
5’ss during catalytic activation may interfere with the use of the 5’ ss for splicing  
         In chapter 4, I demonstrate the importance of association of hnRNP A1 and the U1 
snRNA with the 3’ end of exon 4 in repressing the subsequent U1/U6 switch at the 5’ ss. 
This finding provides first example showing that a structural rearrangement during the 
transition into the Bact/C complex is a naturally occurring point for controlling alternative 
splicing decisions. Building the active site of the spliceosome involves a multitude of 
structural rearrangements, which are described in chapter 4.1. Since the ultimate goal of 
these rearrangements is to bring two splice sites together, the spliceosome components, 
such as U6 snRNA and Prp8, that are involved in these structural rearrangement events 
may interact with the regions around the splice site. Thus, it is possible that the sequences 
around the 5’ ss that are involved in U6 snRNA pairing interactions or Prp8 binding are 
also important in determining the use of the 5’ ss for splicing. 
        In chapter 4.4, the mutation downstream of the -3 to +6 region of the 5’ ss increases 
the splicing of exon 4 by enhancing pairing interactions of U6 snRNA. In chapter 4.5, I 
showed that association of the U5 snRNP components, Prp8, could be repressed by 
hnRNP A1 or the U1 snRNA in the 3’ end of exon 4. If the sequence downstream of the 
5’ ss could be mutated to enhance binding of Prp8, it would further demonstrate that even 
if U1 snRNP binding at the 5’ ss is altered by hnRNP L and A1, enhancing the 
subsequent association of spliceosome components, such as U6 snRNP and Prp8, may 
restore the use of the 5’ ss for splicing. Therefore, the binding affinity of U6 snRNP or 
Prp8 at the 5’ss is the other factor for considering when determining the splicing strength 
of a 5’ss.  
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5.4 Splicing regulators and spliceosome components are combined to regulate 5’ ss 
selection 
        To rearrange the spliceosome structure for two transesterification steps, there are 
about 10 spliceosomal RNA helicases, which are involved in unwinding snRNA duplex, 
mediating pre-mRNA-snRNP interactions and the molecular and structural rearrangement. 
It has been shown that knockdown of these RNA helicases induces specific changes in 
the alternative splicing of some variable exons (Park et al., 2004). This suggests that 
modulations in the activity or concentration of RNA helicases would alter the kinetic 
equilibrium of one or more steps in the splicing reaction. Therefore, while most of studies 
focus on how the splicing regulators control alternative splicing, the intrinsic changes of 
the spliceosome core components could also be a critical point to be considered.  
        The skipping of CD45 exon 4 in the activated T-cells is also likely a good model to 
address the function of the phosphorylation of Prp28 in inducing the skipping of CD45 
exon 4 (Lynch and Weiss, 2000; Rothrock et al., 2003). Although it has been shown that 
PSF and hnRNP L-like are recruited to CD45 exon 4 to induce its skipping in response to 
T-cell receptor signaling pathway (Melton et al., 2007; Oberdoerffer et al., 2008), the 
post-translation modification of spliceosome core components in activated T-cells could 
also play a role in the skipping of exon 4. A recent study showed that the activity of 
Prp28 can be regulated by SRPK2 phosphorylation (Mathew et al., 2008). 
Phosphorylation of Prp28 is required for integration of the tri-snRNP into the 
spliceosome. This indicates that the phosphorylation of prp28 could antagonize the effect 
of the repressed U6 binding at the 5’ ss induced by hnRNP L. Future work will be to 
determine whether Prp28 associates differently with the tri-snRNP in the resting and 
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stimulated JSL1 nuclear extract. These studies will further demonstrate how spliceosome 
components and splicing regulators could be combined to regulate alternative splicing in 
response to the signaling transduction pathways. 
 
5.5 Implications for predicting of 5’ ss selection in alternative splicing 
         The canonical way to determine the strength of the 5’ splice site is based on the 
pairing of the 5’ end of U1 snRNA and the -3 to +6 region of the 5’ splice site. However, 
the U1 snRNP extends its interactions with the pre-mRNA such that ~20 nt on either side 
of the 5’ ss are protected against nucleases (Chabot and Steitz, 1987). Thus, the splicing 
regulators that associate with the regions ~20 nt on either side of the 5’ ss could interfere 
U1 snRNP binding and should be considered an important factor for determining the use 
of the 5’ ss for splicing.  For example, when the sequence upstream of the 5’ ss contains 
the AGU motif, it could be associated with hnRNP A1 and thus the use of the 5’ ss could 
be reduced (Chiou et al., 2013). By contrast, when a 5’ss contains a U-rich tract that 
begins 5-9 nt downstream, the use of the 5’ ss for splicing could be enhanced by TIA-1 
(Del Gatto-Konczak et al., 2000). Moreover, when the sequence downstream of the +6 
position of the 5’ ss is complementary to the U6 snRNA, it probably enhances the 
strength of the 5’ss (Chiou et al., 2013). Investigations on the sequence specificity of 
other splicing regulators and spliceosome components on association with the regions 
around the 5’ ss will bring further insights for determining the splicing patterns.  
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5.5 Conclusions 
          In conclusion, I set up a series of biochemical assays to show that hnRNP A1 and 
the U1 snRNA can cooperatively interact with the 3’ end of CD45 exon 4 in a 
ESS1/hnRNP L-dependent manner, which represses the subsequent catalytic activation of 
the spliceosome. These biochemical approaches provides the framework to demonstrate 
the function of splicing regulators, spliceosome components and exon-defintion 
interactions in mediating splicing regulation, particularly the 5’ ss selection. Future 
characterization of ESS1-repressed exon-defined complex, the U1-5’ss complex 
containing various sequences surrounding the 5’ss and complexes assembled in the 
stimulated JSL1 nuclear extract will provide insight into both the 5’ ss selection for 
splicing and CD45 splicing regulation in response to TCR-signaling. 
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Chapter 6 
Materials and Methods 
 
6.1 Plasmids and RNA substrates 
         The DNA fragment containing CD45 exon 4 with either wild-type ESS1 or mutated 
ESS1 and its flanking introns was inserted into the upstream region of the AdML PPT 
and exon in pAdML (Rothrock et al., 2005). The pAdML was a kind gift from K.J. Hertel 
and the RNA generated from pAdML was described previously (Anderson and Moore, 
1997; Hertel and Maniatis, 1999). To allow the splicing complexes assembled on the 
RNA substrates to be purified, three MS2 binding site was inserted to the 3’ end of the 3’ 
AdML exon.  
         The template for in vitro transcription was generated from the plasmid described 
above by PCR. The RNA was synthesized by T7 polymerase. The resultant RNA 
substrate contains a 150 nucleotide (nt) 5’ intron, a 197 nt 5’ exon 4, a 260 nt 3’ intron 
and a 56 nt 3’ AdML exon followed by a 120 nt MS2 binding site. The 60 nt ESS1 
sequence is located at -110 to -170 of exon 4 (Figure 2.4A). PCR mutagenesis was used 
to introduce mutations into the -6 to -24 region of exon 4 to generate template for in vitro 
transcription of the substrates containing R, Q, A and U mutation. The sequences of  Q, A 
and U mutation are shown in Figure 2.7A.  
 
6.2 In vitro splicing and spliceosome assembly 
        Repressed (R), derepressed (D) RNA and the RNA substrates containing various 
mutations (Q, A and U) at the 3’ end of exon 4 were transcribed from the PCR products 
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that contain a T7 promoter sequence (Figure 3.2). The downsteam AdML exon contains a 
stronger AdML polyprimidine tract, which enhances the formation of the splicing 
complexes on the RNA substrates. The 3’ end of the RNA contains the three copies of 
MS2 hairpin sequence, which can be bound by MS2MBP fusion protein and functions as 
a tag for the splicing complex isolation. 
         In vitro splicing reactions and spliceosome assembly were carried out as described 
previously (House and Lynch, 2006),with some modifications as described in 6.2.1 and 
6.2.2 For spliceosome assembly, the splicing reactions or the individual fractions from 
the gradient-fractionated splicing reaction were separated and visualized using native 
polyacrylamide gel in the presence or absence of heparin, as indicated in the figure. 
 
6.2.1 In vitro splicing assays 
         Unlabeled RNA substrates (10 nM) were incubated with 60% JSL1 nuclear extract 
in a total volume of 12.5 µl under splicing condition, which contains (final concentration): 
12 mM Tris-HCl, pH7.5, 3.2 mM MgCl2, 4 mM ATP, 20 mM CP, 0.5 mM DTT, 0.125U 
RNasin (Promega), 60 mM KCl, 0.1 mM EDTA, and 12% glycerol. Reactions were 
incubated for 90 min at 30°C; then the RNA was recovered from the reactions by 
protease K treatment, phenol-chloroform extraction and EtOH precipitation. The 
recovered RNA was analyzed by RT-PCR as described previously (Rothrock et al., 
2005). The primers for analyzing the repressed and derepressed substrates were within 5’ 
intron and 3’ exon. 
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6.2.2 Spliceosome assembly assays 
         12.5 µl splicing reactions containing uniformly 32P-labeded RNA were incubated 
for 60 min and then treated with 1µl heparin (50µg/µl) to allow the complexes formed in 
the splicing reactions to be separated by the native gel. The 4% native polyacrylamide gel 
(Acrylamide/Bisacrylamide ratio of 80:1) was made and run in 25 mM Trsi-glyciune 
buffer at 250 V for 4 hour at room temperature. The gels were dried under vaccum and 
visualized by phoaphorimager.             
         For analyzing splicing complexes in gradient fractions, addition of heparin into 
fractions was not required for the complexes to be separated in a native but it affects the 
B and C complex assembly in a native gel. Of 215 µl gradient fraction, 10 µl was directly 
loaded into the native polyacrylamide gel or treated with 1µl heparin (5µg/µl) and then 
loaded into the gel.  
 
6.3 Oligonucleotide-directed RNase H cleavage 
        To cleave the snRNA by the endogenous RNase H in JSL1 nuclear extract, 60% 
nuclear extract was incubated for 30 min at 30°C under splicing condition in the presence 
or absence of 8 µM oligonucleotide complementary to the target snRNA. The sequence 
of the oligonucleotides was described previously (House and Lynch, 2006). The RNA 
substrates were then added into the snRNA-inactivated nuclear extract under splicing 
condition, which then proceeded into spliceosome assembly or UV crosslinking assays. 
        For cleavage of U6 snRNA of the complexes purified from the spliceosome 
assembly reactions, the MS2MBP-affinity selected complexes were incubated for 5 min 
on ice in the presence of U6f oligonucleotide with the concentrations as indicated in 
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Figure 4.11 (Konforti and Konarska, 1994). The amount of the cleavage was determined 
by primer extension. 
 
6.4 Gradient separation of splicing reactions and MSMBP affinity purification of 
splicing complexes         
        Standard splicing reactions containing the RNA substrate pre-bound by 10-fold 
excess of MS2-MBP fusion protein were incubated for 90 min at 30°C to allow the 
accumulation of the B and C complex. 250 µl splicing reaction was layered on a 15-35% 
(v/v) glycerol gradient containing buffer GS (20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 4 
mM MgCl2 and 1 mM DTT). The gradients were centrifuged at 45000 rpm for 3 hours at 
4°C in a SW50.1 rotor and then harvested manually in a 215-µl fractions from top into 21 
aliquots. The splicing complexes in fractions were analyzed by native gel as described 
above. The early (E), middle (M), and late (L) fractions, which contain similar 
complexes, were pooled and passed once through a column containing 250 µl amylose 
beads (NEB) pre-equilibrate with buffer GSG (buffer GS containing 10% glycerol). The 
column was washed twice with 1 ml buffer GSG. Bound complexes were eluted three 
times with 125 µl elution buffer (buffer GSG containing 30 mM Maltose). The combined 
second and third elution contains approximately 0.1 pmole complexes, which is 10% of 
the input transcript in the L or M fractions. Because the substrate levels of the E fractions 
from the typical splicing reactions were much less, the E fractions from gradient 
separation of the ATP-depleted splicing reactions were pooled for the complex 
purification, which was used for the following western blot analysis.  
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6.5 Isolation and analysis of splicing complexes 
        The early (E), middle (M), and late (L) fractions were separated from the standard 
splicing reactions (Figure 1C). They were pooled for the following MS2MBP-affinity 
purification of splicing complexes as previously described (Schneider et al., 2010b; 
Sharma et al., 2005), with some modification as described in supplementary data.  
        The RNA recovered from the purified complexes was separated on 8% urea-PAGE 
gel followed by either silver-staining (Bio-rad) or exposure to phosphorimager to 
determine the levels of snRNAs or the 32P-labeled splicing precursor, intermediates and 
product. The proteins from ~0.02 pmole of purified complexes were separated by SDS-
PAGE and analyzed by western blot. The antibodies aganist hnRNP L, hnRNP A1, 
Prp19, CDC5L, SAP130, and Prp22, were all from Abcam; PLRG and SPF27 antibody 
were from bethyl laboratories; U2AF65 and MBP antibody were from Sigma.  
 
6.6 Psoralen crosslinking 
          Pooled middle (M) fractions or the splicing reactions incubated for 30 min at 30°C 
were placed on ice. AMT-poralen was added to a final concentration of 24 µg/µl and the 
reactions were irradiated with 365 nm light for 10 min on ice (Sharma et al., 2005). The 
RNA-RNA cross-links were mapped by primer extension using the primer that was 
complementary to nucleotide 56-76 of the downstream intron.  
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6.7 UV crosslinking of complexes assembled on site-specifically labeled RNA 
substrate 
          Synthesis of RNA substrates containing a single 32P-label was performed as 
described (Sharma et al., 2011). The standard splicing reactions containing the site-
specific labeled RNA (5000 cpm) incubated for 30 min at 30°C were placed on ice, 
irradiated with 254 nm light for 20 min on ice and digested with RNase A and T1 for 20 
min at 37°C. The crosslinked splicing reactions were separated by SDS-PAGA and 
analyzed by phosphorimager. The identities of the crosslinked proteins were determined 
by immuno-precipitaion of crosslinked splicing reactions (Rothrock et al., 2005). 
 
6.8 SHAPE analysis of the purified U1-5’ss complex 
        The 5’ ss RNA fragment containing the region ranging from -45 to +76 relative to 5’ 
ss on the CD45 exon 4 is transcribed in vitro. The 5’ ss RNA fragment was incubated 
with nuclear extract under the conditions as described in Chapter 6.2.  250µl of the 
assembled reactions was used for the MS2MBP-affinity selection. 30 µl of the purified 
complexes was incubated with BzCN to reach the concentrations as shown in Figure 2.9C 
at room temperature (Konforti and Konarska, 1994). The regions of U1 snRNA that react 
with BzCN were determined by primer extension. The sequence of the primer for primer 
extension was described previously (House and Lynch, 2006). 
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